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Aims of the study 
The majority of patients with locally advanced cervical cancer are treated with 
chemoradiotherapy. Approximately 55% of these patients show progressive disease within 5 
years after diagnosis, and side effects in organs within the pelvis after radiation treatment 
are frequent. It is therefore a lot to gain on finding biological characteristics of the disease 
that can be used to predict the outcome more accurately than the clinical information 
currently used. Chromosomal alterations, like gains and losses, are frequent in cervical 
cancer. Such DNA copy number alterations may deregulate the expression of affected genes 
and change cell behavior, however, their biological significance in cervical cancers have not 
been clarified.
The overall aim of this work was to explore the potential of DNA copy number alterations 
as biomarkers for identification of patients at risk for failure or for development of targets 
for therapeutic intervention. The preferred technique for detecting copy number alterations 
is array comparative genomic hybridization (aCGH). This technique provides relative copy 
numbers, which are influenced by tumor ploidy and the normal cell content of the clinical 
specimen, leading to unreliable results when data are compared across patients. An 
improvement of the current analysis methods was therefore required to handle these 
problems. The specific aims of the work were to: 
 Develop a tool for genome-wide calculation of absolute DNA copy numbers from 
clinical aCGH data that enabled comparisons across patients despite differences in 
tumor ploidy and normal cell content of the clinical specimens.  
 Explore the importance of DNA copy number alterations for the carcinogenesis and 
chemoradioresistance of cervical cancers by aCGH analysis.  
 Investigate the functional role of selected DNA copy number alterations by 
integrating the data with gene expression and ontology information of the same 
patients.  
 Evaluate the usefulness of DNA copy number alterations and their target genes as 
biomarkers for the clinical outcome. 
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1Introduction
Cervical cancer
Epidemiology  
Cervical cancer is the second most common cause of cancer-related death among women 
globally, and the number-one cause of cancer-related death in women in developing 
countries (Lehoux, D'Abramo, and Archambault 2009). From 2004-2008, 284 new cases 
were diagnosed in Norway each year (Cancer Registry of Norway 2010). International 
Agency for Research on Cancer (IARC) estimated 493,000 new cases in 2002 worldwide, 
and the number of deaths was 274,000 (Parkin et al. 2005). The peak incidence of the 
disease occurs in women over 40 years of age. The introduction of the Pap smear has 
reduced the overall death rate by approximately 74% since the tests were first implemented 
(Cervical Cancer Statistics 2007). Therefore 80% of the incidences are occurring in 
developing countries, where cervical cancer prevention programs are not available.  
Risk factors 
The primary risk factor for cervical cancer is the Human Papilloma Virus (HPV). There are 
several types of HPV, which vary in their ability to transform the cervical epithelium 
(Cannistra and Niloff 1996). Low-risk varieties, such as HPV 6 and 11 are commonly 
associated with CIN I, which do not usually progress to invasive disease. The high-risk 
types, such as HPV 16, 18, 31, 33, and 35 are often associated with moderate dysplasia 
(CIN II) and severe dysplasia (CIN III) or carcinoma in situ and are observed in more than 
99% of patients with invasive cervical cancer (Lehoux et al. 2009). The highest incidence of 
HPV infection is between the age of 20 and 30, suggesting a long latency period between 
infection and cancer appearance (Lazo 1999). Other risk factors have been identified, 
including poverty, high parity, sexual intercourse at an early age, multiple sexual partners, 
smoking, eating habits, and weakened immune system (Hulka 1982;Reeves, Rawls, and 
Brinton 1989).
Histological subtypes 
The three major histological types of invasive cervical cancer are squamous cell carcinoma 
(SCC), adenocarcinoma (AC), and adenosquamous carcinoma (ASC), where SCC 
comprises 80-85% of the cases and AC and ASC together comprise approximately 15% of 
2the cases (Baalbergen et al. 2010). SCC arises from the multilayered squamous epithelium 
of the ectocervix and transformation zone, whereas AC arises from the glandular epithelium 
of the endocervix (Szalmas and Konya 2009). 
Staging
Staging of invasive cervical cancer is usually described in terms of the FIGO (International 
Federation of Gynecology and Obstetrics) system based on clinical criteria like size, depth 
of penetration within the cervix, and spread within and beyond the cervix (Fig. 1) (Koyama, 
Tamai, and Togashi 2007). Stage I tumors are limited to the cervix, and are divided into 
stage 1A, 1B1, and 1B2 depending on the penetration depth. Stage II tumors extend beyond 
the cervix to the upper two thirds of the vagina (IIA) or the parametrial tissue (IIB), but not 
to the pelvic side wall. Stage III tumors have spread to the lower third of the vagina (IIIA) 
or to the pelvic side wall (IIIB). Stage IV tumors have invaded the mucosa of the bladder or 
rectum (IVA) or have spread to distant sites outside the pelvis (IVB). 
Fig. 1: Staging of cervical cancer according to FIGO. Adapted from (Camiso et al. 2007). 
3Treatment and prognosis 
The choice of treatment for invasive cervical cancer depends primarily on tumor stage, 
although factors like the location of the tumor within the cervix, histology, patient age, 
general health, childbearing plans, and pregnancy also affect the therapeutic options (Health 
MD: How is Cervical Cancer Treated? 2010). At stage IA, hysterectomy or conization is 
performed. The five-year survival rate for these patients exceeds 95%. Patients with stage 
IB or early stage IIA receive either surgery or chemoradiotherapy, which produces 
equivalent results with a five-year survival rate of 80%. At the locally advanced stages IIB, 
III, and IVA, chemoradiotherapy is the treatment of choice. Both external irradiation and 
brachytherapy are given, combined with adjuvant cisplatin-based chemotherapy, which has 
shown to increase the effect of the radiotherapy (Eifel 2006). The five-year survival rates 
are 65, 40, and less than 20% for stage IIB, III, and IVA. Patients with stage IVB may also 
benefit from local radiotherapy, which is combined with carboplatin and 5-FU-based 
chemotherapy. At this stage the disease is generally not considered to be curable.
Biomarkers 
Standard diagnostic procedures for cervical tumors are currently based on clinical data, 
which, in most cases, provide precise information on tissue origin, tumor type, stage, grade, 
and the possibility for complete surgical tumor removal (Dietel and Sers 2006). Up to now, 
these data are the rational basis for therapy design. However, they do not fully reflect the 
aggressiveness of the disease and two patients harboring the apparently “same” type of 
tumor in a seemingly “identical” stage often show different therapeutic outcome. It is 
therefore a considerable need for biomarkers that can be used in addition to the standard 
clinical information, to predict the therapeutic outcome and thereby aid the clinical decision-
making (Dietel and Sers 2006). Biomarkers for design of targeted therapeutics, directed 
towards the treatment resistant cells and/or interfering with key signaling pathways in the 
tumor response, are also required, in particular for the patients receiving 
chemoradiotherapy. Development of novel radiosensitizing agents can enable reduction in 
the radiation dose and thereby side effects while retaining the tumor control probability. 
General characteristics of cancer
Cancer is characterized by a group of cells displaying uncontrolled growth, invasion and 
destruction of adjacent tissues, and sometimes spread to other locations in the body 
4(metastasis) (Alberts et al. 2002). These are malignant features and distinguish cancers from 
benign tumors, which are self-limited and do not invade or metastasize. Cancers are 
classified according to the tissue and cell type from which they arise. The main types are 
carcinoma (epithelial tissue), glioma (brain tissue), sarcoma (soft tissue and bone), and 
leukemia/lymphoma (haematopoietic tissue). 
Cancer development 
Cancer is, in essence, a genetic disease, and alterations in oncogenes, tumor suppressor 
genes, and stability genes are responsible for the initiation and progression of the disease in 
a process called carcinogenesis (Vogelstein and Kinzler 2004). Both genetic and epigenetic 
alterations are involved, leading to changes in the gene expression and thereby cell 
behavior.
Carcinogenesis is a multi-step process, typically a progression from benign lesions to 
malignant tumors (Fig. 2) (Stewart and Kleihues P. 2003). All living cells will 
probabilistically suffer from errors in the genome. Normally the body is protected against 
their potentially lethal effects. However, the cellular correction machinery may fail, 
especially in environments that make errors more likely to arise and propagate. The 
progressive errors then slowly accumulate until the cell begins to act contrary to its function 
in the organism and a malignant lesion is formed.     
Fig. 2: Tumor initiation and progression
Malignant tumors are generally believed to be monoclonal, meaning that each tumor arises 
from a single cell (Nowell 1976). This cell will acquire sequential accumulation of genetic 
and epigenetic alterations in genes responsible for the control of cellular proliferation, cell 
5death and the maintenance of genetic integrity. Selective clonal expansion will then lead to 
progression towards cancerous growth.  
Tumor progression is not only a process of alterations in cancer cells, but also the 
environment contributes substantially to the malignancy. This was hypothesized already in 
1889 by Paget in his “seed and soil” hypothesis, suggesting that the cancer cells (seeds) 
need specific organ microenvironments (soils) in order to proliferate (Paget 1989). Tumor 
progression is the product of an evolving crosstalk between different cell types within the 
tumor and its surrounding supporting tissue, called the tumor stroma. Cancer cells can alter 
their stromal environment by producing growth factors and proteases to form a permissive 
and supportive environment for tumor progression (Mueller and Fusenig 2004). Such 
alterations involve induction of angiogenesis, degradation and remodeling of the 
extracellular matrix, inflammation and production of a range of factors that promote cell 
proliferation.  
Genetic and epigenetic alterations  
Genetic alterations include subtle sequence changes, amplifications, deletions, and 
translocations (Fig. 3). The genetic alterations may either be random, leading to no growth 
advantage, or important for the malignant progression, driving the tumor towards a more 
aggressive state (Ried et al. 1999). Subtle sequence changes involve base substitutions or 
deletions or insertions of nucleotides. The simplest alteration is a point mutation, where a 
single nucleotide is exchanged for another. If mutations in key regulatory genes are not 
repaired, the cells will alter their behavior and cancer may arise. Humans with defects in 
repair mechanisms, such as nucleotide-excision repair or mismatch repair, are shown to be 
more susceptible to certain types of cancers (Lengauer, Kinzler, and Vogelstein 1998). 
Amplification is a copy number increase of a restricted region of a chromosome arm, or of 
the whole chromosome arm, and is often associated with overexpression of some of the 
affected genes. Amplifications can be divided into small chromosomal segments that may 
be present at high level, usually denoted high-level amplification or just amplification, and 
larger chromosomal regions generally present at lower levels, called gains. Deletion is a 
copy number loss of a chromosome arm or of a region of the chromosome arm. It may 
involve a loss on one of the chromosomes in a pair, called a heterozygous deletion, or loss 
of the same region on both chromosomes, called a homozygous deletion.  
6A consequence of severe changes in the copy number of chromosomes is aneuploidy, which 
is caused by mitotic abnormalities (Munger 2002). Aneuploidy occurs during cell division 
in cases where the chromosomes do not separate properly between the two cells. Cancer 
cells are frequently aneuploid and can contain either less or more than two copies of the 
chromosomes. The importance of gene copy number alterations and aneuploidy for the 
carcinogenic process is not clear and probably varies substantially between tumors. Due to 
differences in the mechanisms by which tumors are initiated, either in the individual 
genotype or in the particular cell type in which the tumor arises, some tumors accumulate a 
number of alterations, whereas others may evolve by mechanisms that result in little 
chromosomal changes (Albertson et al. 2003).
Translocations are caused by rearrangement of parts between nonhomologous 
chromosomes. They can involve two or more chromosomes and are either balanced, 
involving an even exchange of material, or unbalanced, where the exchange of 
chromosomal material is unequal, resulting in extra or missing chromosomal regions 
(Lengauer et al. 1998). Chromosomal translocations can result in the generation of new 
gene products, either by the fusion of genes or by bringing genes close to enhancer or 
promoter elements, hence leading to their altered expression (Nambiar, Kari, and Raghavan 
2008). Translocations are considered the primary cause of many cancers, including 
lymphoma, leukemia, and some solid tumors. 
Fig. 3: Genetic alterations found in cancer cells
Epigenetic alterations are changes in gene expression caused by mechanisms other than 
changes in the DNA sequence itself. A key mechanism in epigenetic regulation of gene 
7expression is DNA methylation (Wajed, Laird, and DeMeester 2001). This is an enzyme-
induced chemical modification of the DNA structure where a methyl group is added to the 
DNA, mostly at CpG sites, to convert cytosine to 5-methylcytosine.  Epigenetic alteration 
also involves post translational modification of histone proteins (Herceg and Hainaut 2007). 
If the amino acids that make up the histones are changed, this can lead to a modified shape 
of the histone sphere and an incomplete unwinding of the DNA during replication.
Genetic instability 
Genetic instability is the rate of alterations observed in a cell population at a certain time 
point, and is seen primarily at the chromosomal level (Lengauer et al. 1998). Due to genetic 
instability, subpopulations with different genetic alterations may emerge successively and 
coexist within tumors, reflecting clonal divergence (Fig. 4) (Georgiades et al. 1999). 
Assessment of this intratumor heterogeneity provides important clues of the genetic steps 
involved in carcinogenesis. Since the heterogeneous alterations have emerged after the 
homogeneous ones, the chronological order of the alterations indicates how the tumor has 
evolved (Lyng et al. 2004). Aneuploidy may be a consequence of high genomic instability, 
although it may also arise from a single genetic event.  
The intratumor heterogeneity in genetic alterations is a major challenge in the treatment of 
cancer since different subpopulations may have different capacities for growth, 
differentiation and metastasis formation, as well as sensitivity to radiation and 
chemotherapeutic agents (Barranco et al. 1994;Vogelstein and Kinzler 1993).  Treatment 
results in selective killing of sensitive populations, whereas the resistant ones survive 
(Barranco et al. 1988). Continued treatment may lead to total resistance, not only to the 
initial agent or combination, but to other agents as well (Rothenberg and Ling 1989). 
Knowledge of the genetic heterogeneity within tumors may therefore be crucial for the 
handling of the disease.
8Fig. 4: Schematic diagram showing the evolution of the subpopulations A, B, and C with 
different genetic alterations. Subpopulation B has evolved from subpopulation A, and 
subpopulation C has evolved from subpopulation B.  
Cancer genes 
In the last decades, many genes involved in carcinogenesis of various cancers have been 
discovered. The regulation of these genes facilitates signal transduction, mediates cell 
division, differentiation or cell death, and maintains the integrity of genetic information by 
DNA repair and similar processes (Stewart and Kleihues P. 2003). The genes are believed to 
be targets for the genetic alterations and fall into three major categories; oncogenes, tumor 
suppressor genes, and stability genes. In addition, microRNA (miRNA) is a recently 
discovered class of small non-coding RNAs that regulate gene expression post-
transcriptionally. 
Oncogenes are genes that, when mutated or expressed at high levels, are capable of 
transforming a normal cell into a tumor cell and therefore contribute to the formation of 
cancer (Vogelstein and Kinzler 2004). The normal gene counterparts are referred to as 
proto-oncogenes. An activating somatic mutation in one allele of an oncogene is generally 
sufficient to confer a selective growth advantage on the cell, and the activation of an 
oncogene is therefore dominant. Oncogene activations can result from chromosomal 
translocations, gene amplifications, or from subtle intragenic mutations affecting crucial 
residues that regulate the activity of the gene product. The RAS family of oncogenes was 
among the first that was recognized as being mutated in a variety of human cancers, 
whereas the MYC oncogene is frequently overexpressed by gene amplification (Stewart and 
Kleihues P. 2003).
9Tumor suppressor genes protect the cell from becoming a tumor cell. Their alteration during 
carcinogenesis results in the loss of functional property essential for the maintenance of 
normal cell proliferation (Vogelstein and Kinzler 2004). The loss of function of a tumor 
suppressor gene is a recessive mechanism, implying that both alleles must be affected to 
switch it off. Inactivation of tumor suppressor genes can arise from missense mutations, 
deletions, insertions, or from epigenetic silencing. TP53 is the most commonly altered 
tumor suppressor gene in human cancers, being altered in over 50% of most tumor types 
(Stewart and Kleihues P. 2003).
Stability genes keep genetic alterations to a minimum, and when they are inactivated, 
mutations in other genes occur at a higher rate. Stability genes are involved in DNA repair 
and include mismatch repair genes (MLH1, MSH2, PMS2), nucleotide-excision repair genes 
(XPA, DDB2), and base-excision repair genes (MUTYH), which are responsible for 
repairing mistakes occurring during normal DNA replication or induced by mutagenic 
exposure (Vogelstein and Kinzler 2004).  Stability genes are also involved in control 
processes, such as mitotic recombination and chromosomal segregation (ATM, BRCA1,
BLM, RECQL4). As with tumor-suppressors, both alleles need to be inactivated to have full 
effect.
MicroRNAs are evolutionarily conserved, small, single-stranded molecules that do not 
encode proteins, but instead suppress the expression of protein-coding genes by blocking 
translation, degrading mRNA, or both (Anglicheau, Muthukumar, and Suthanthiran 2010). 
More than 700 miRNAs have so far been identified in the human genome. A single miRNA 
can regulate the expression of hundreds of mRNAs or proteins, and each mRNA can be 
targeted by multiple miRNAs that can interact with each other, either by synergism or 
competition. It is believed that most protein-coding genes are regulated by miRNAs, and it 
has been shown that miRNAs play an important role in diverse biological processes like 
development, differentiation, cell proliferation, apoptosis, and oncogenesis (Valencia-
Sanchez et al. 2006). Up- or down-regulation can be due to amplification, deletion, 
regulation of a transcription factor, or methylation/demethylation. miRNA genes can 
function either as oncogenes or tumor suppressor genes depending on their targets in a 
specific tissue (Croce 2008), and many miRNAs have been shown to locate to chromosomal 
regions that undergo rearrangements, deletions, and amplifications in cancer cells (Calin et
al. 2004). Dysregulated expression of miRNAs has already been associated with several 
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cancers. Of interest, miR-127 has been shown to be overexpressed in cervical cancer 
patients with lymph node metastasis (Lee et al. 2008). Moreover, anti-miR-199a has been 
shown to inhibit cervical cancer cell growth, suggesting miR-199a as a potential therapeutic 
target for cervical cancer therapy (Lee et al. 2008). 
Carcinogenesis in cervical cancer 
The multistep process 
Cervical cancers progress in a multistep process, from preinvasive cervical intraepithelial 
neoplasia (CIN) to invasive stages (Grubisic et al. 2009). The majority of cervical cancers 
originate from the squamous epithelium near the opening of the cervix (Alberts et al. 2002), 
where the proliferation normally occurs only in the basal layer (Fig. 5A). The newly 
generated cells move towards the surface, differentiate, and form flattened, keratin-rich, 
non-dividing cells that are sloughed off as they reach the surface. It is not unusual to find 
patches in which this organization is disturbed in a way that suggests the beginning of a 
cancerous transformation, called cervical intraepithelial neoplasia (CIN). These changes can 
be low-grade (CINI), moderate (CINII), or severe (CINIII) (Szalmas and Konya 2009).  
In the low-grade lesions, dividing cells are no longer confined to the basal layer, but occupy 
the lower third of the epithelium (Fig. 5B). Most of these lesions will spontaneously regress; 
however, about 10% might progress to become high-grade lesions. Most of the epithelial 
layers will then be occupied by undifferentiated dividing cells, which are usually highly 
variable in cell size and shape (Fig. 5C). If remained untreated, the abnormal tissue may 
persist and stop progressing or it may regress spontaneously. However, in almost half of the 
cases, progression will occur, giving rise to an invasive carcinoma where cells cross or 
destroy the basal lamina, invade the underlying tissue, and metastasize (Fig. 5D).  
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Fig. 5: The stages of progression in the development of squamous cell cervical carcinoma. 
Adapted from (Alberts et al. 2002).
HPV infection 
Infection with high-risk HPV (HR-HPV) is a necessary, but insufficient, contribution to 
cervical cancer, with additional viral and host genetic events required to drive cells to the 
malignant phenotype (Pett and Coleman 2007). HR-HPV is detected in 99.7% of the cases 
and also in the vast majority of high-grade neoplasia (Lehoux et al. 2009). HPV 16 and 18 
are the most prevalent types, accounting for about 70% of all cases. In the normal viral life 
cycle, HPV genomes exist in a circular or episomal state and are thought to be retained in 
basal cells of the squamous epithelium at approximately 50-100 copies per cell (Fig. 6)  
(Bedell et al. 1991;Stanley et al. 1989). In the episomal form, the expression of the viral 
oncogenes E6 and E7 is tightly regulated. However, in most cervical cancers (90%), 
truncated viral genomes are integrated into host DNA, resulting in deregulation of viral 
oncogene expression (Pett and Coleman 2007). Integration is not a part of the HR-HPV life 
cycle and represents a by-product of viral infection, leading to increased expression and 
stability of transcripts encoding the E6 and E7 proteins. This effect is restricted to HR-HPV. 
Integrated HPV may be viewed as selectable because it represents a form of the virus that is 
resistant to host mechanisms of viral clearance, enabling infected cells to maintain viral 
oncogene expression and avoid cell death. 
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Fig. 6: Significance of HR-HPV integration events detected in cervical carcinomas. Adapted 
from (Pett and Coleman 2007). 
The viral proteins E6 and E7 produced by HR-HPV types are critical for malignant 
transformation, due to their ability to bind and inactivate the tumor suppressor proteins 
TP53 and RB1 (Cannistra and Niloff 1996). E6 inactivates the function of wild-type TP53 
by enhancing its degradation, resulting in prevention of apoptosis. It can also interfere with 
cellular apoptotic pathways by a TP53-independent mechanism by binding to the tumor 
necrosis factor receptor TNFRSF1A and FAS-associated death domain protein FADD, 
leading to the degradation of FADD and the caspase CASP8 (Garnett and Duerksen-Hughes 
2006). E7 binds to RB1, relieves its repression of the E2F transcription factors, and causes 
the cell to reenter S-phase.   
The mechanism by which HPV integrates is not fully understood, but there is a clear 
predilection for integration at chromosomal common fragile sites (CFSs) (Thorland et al.
2003;Thorland et al. 2000;Wentzensen, Vinokurova, and von Knebel 2004;Yu et al. 2005), 
which are DNA regions of profound genomic instability that span from several hundred 
kilobases to greater than 9 Mb (Richards 2001). The most frequently observed integration 
site, particularly in cervical cancers positive for HPV 18, is the region of the MYC oncogene 
at chromosomal band 8q24 (Durst et al. 1987;Peter et al. 2006;Wentzensen et al.
13
2002;Ferber et al. 2003b). Another active CFS is the FRA3B locus at 3p14.2, which is 
frequently altered in cervical cancers. Recurrent integration has also been observed at the 
TERT (Ferber et al. 2003a) and FANCC (Wentzensen et al. 2002;Ferber et al. 2003b) loci, 
at chromosomal bands 5p15 and 9q22, respectively.  
HR-HPV infection also leads to genomic instability, which is reflected in the high 
proportion of aneuploid cervical tumors. The HPV E6 and E7 proteins disturb the 
centrosome replication during cell division, leading to increased centrosome numbers, 
aberrant mitotic spindle pole formation, and aneuploidy (Duensing et al. 2000). In fact, 
abnormal, tripolar mitoses have been described as diagnostic markers of HR-HPV positive 
lesions. E6 expressing cells show mostly gene amplifications, abnormalities consistent with 
TP53 loss, whereas E7 expressing cells often displays gains and losses of entire 
chromosomes and are aneuploid (White, Livanos, and Tlsty 1994). Hence, in addition to 
containing compromised surveillance functions, HR-HPV E6 and E7 expressing cells 
constantly produce mitotic abnormalities even when expressed from viral episomes, which 
greatly increases genomic instability and the probability of malignant progression 
(Duensing et al. 2001).
Genetic alterations in cervical cancer 
Genome wide screening of chromosomal alterations in cervical cancer has revealed genetic 
changes on all chromosomes, and identified several chromosomal regions that are 
recurrently affected. The most frequent alterations are gain of 1q, 3q, 5p, and 20q and loss 
of 2q, 3p, 4p, 4q, 11q, and 13q (Heselmeyer et al. 1997;Lyng et al. 2004;Rao et al.
2004;Ried et al. 1999;Umayahara et al. 2002). The gain of 3q and loss of 3p are especially 
frequent, where the former has been found to define the transition from preinvasive to 
invasive cervical carcinoma (Heselmeyer et al. 1996;Umayahara et al. 2002). The gain of 
20q has been described by a number of studies (Dellas et al. 1999;Kirchhoff et al.
1999;Narayan et al. 2003;Umayahara et al. 2002) and has in other solid tumors, such as 
breast, colon, and gastric carcinomas been associated with a selective growth advantage and 
a more aggressive metastatic phenotype (Hermsen et al. 2002;Hodgson et al.
2003;Kallioniemi et al. 1994;Muleris et al. 1994;Weiss et al. 2003). 
Cervical cancers also show substantial intratumor genetic heterogeneity due to the high 
chromosomal instability (Ried et al. 1999). Loss of 3p and gain of 3q are seldom 
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heterogeneous and are therefore believed to play a role in early development of the disease 
(Guo et al. 2001;Lyng et al. 2004). On the other hand, loss of chromosome 4 and 6q, and 
gain of 2p have been shown to be both frequent and heterogeneous, indicating that they lead 
to a significant growth advantage and that they are important for tumor progression at a later 
stage (Lyng et al. 2004).
Although several genetic alterations have been suggested to play a role in the carcinogenesis 
of cervical cancer, most of the target genes are unknown and the biological meaning of the 
alterations is poorly understood. The low resolution of the CGH-technique used in many of 
the studies, have led to difficulties in limiting the gained and lost regions. This has made it 
difficult to distinguish between the genes playing a functional role during carcinogenesis 
and those that are passengers. Moreover, the number of samples included in the studies has 
often been limited, reducing the statistical reliability of the analyses and therefore the ability 
to discover genetic alterations important for the clinical outcome. Application of the aCGH 
technique on a large sample set of tumors may therefore lead to novel insight into the 
genetic alterations of cervical cancers and their potential as biomarkers. 
Biological consequences of genetic alterations
Changes in the cancer genome are believed to manifest essential alterations, known as 
cancer hallmarks, associated with tumor cell phenotype and physiology that collectively 
promote malignant growth. These cancer hallmarks are self-sufficiency in growth signals, 
insensitivity to antigrowth signals, evasion of apoptosis, limitless replicative potential, 
sustained angiogenesis, and tissue invasion and metastasis (Hanahan and Weinberg 2000). 
Also metabolism and endocytosis are considered hallmarks of physiological changes in 
cancer cells. The genomic instability is a way of evolving populations of pre-malignant and 
malignant cells to reach these biological endpoints in the process of carcinogenesis. 
Self-sufficiency in growth signals implies that the tumor cells generate many of their own 
growth signals by altering extracellular growth signals, transcellular transducers of those 
signals, or intracellular circuits that translate the signals into action (Mees, Nemunaitis, and 
Senzer 2009). This is in contrast to normal cells which require mitogenic growth signals to 
move from an inactive state into an active proliferative state (Hanahan and Weinberg 2000). 
Tumor cells are therefore less dependent on exogenous growth stimulation.  
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Insensitivity to antigrowth signals implies that cancer cells have the ability to evade 
antiproliferative signals, such as soluble growth inhibitors and immobilized inhibitors, in 
order to progress (Hanahan and Weinberg 2000). These signals block proliferation by either 
forcing the cells out of the active proliferative cycle into the G0 phase of the cell cycle, or by 
inducing the cells to permanently give up their proliferative potential by making them enter 
into postmitotic states. At the molecular level, most antiproliferative signals are funneled 
through RB1 and its two relatives, RBL1 and RBL2. Disruption of the RB1 pathway allows 
proliferation, causing cells insensitive to antigrowth factors that normally operate along this 
pathway to block progression (Weinberg 1995).  
Evasion of apoptosis is, in addition to proliferation, important for the tumor cell population 
to expand in number. Apoptosis, programmed cell death, is triggered by a variety of 
physiologic signals, and will unfold in a precisely choreographed series of steps, including 
disruption of cellular membranes, breakdown of cytoplasmic nuclear skeletons, degradation 
of chromosomes, and fragmentation of the nucleus (Fulda 2009). Apoptosis is essential to 
all types of cancer and the apoptotic program is present in a latent form in almost all cell 
types in the body.
Limitless replicative potential is a characteristic of most cancer cells, which is due to their 
ability to maintain their telomeres, the ends of chromosomes, at a length above critical 
threshold. Telomeres are composed of several thousand repeats of a short 6 bp sequence 
element. In normal cells, DNA polymerases are unable to completely replicate the 3’ ends 
of chromosomal DNA, resulting in progressive shortening of the telomeres. Telomeres will 
thereby lose their ability to protect the ends of chromosomal DNA, which eventually leads 
to death of the affected cell, a process called senescense (Counter et al. 1992). Most cancer 
cells maintain their telomeres by upregulating the expression of the telomerase enzyme, 
which adds hexanucleotide repeats onto the ends of telomeric DNA, while the remainder is 
activating a mechanism which maintains telomeres through recombination-based inter-
chromosomal changes of sequence information (Bryan and Cech 1999).  
Sustained angiogenesis is the process by which cancer cells induce and sustain the growth 
of new blood vessels. Oxygen and nutrients are crucial for cell function and survival, and 
are supplied by the vasculature. Cells within aberrant proliferative lesions initially lack the 
angiogenic ability, reducing their capability to expand. Cancer cells on the other hand 
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overcome this restriction by inducing and sustaining angiogenesis (Hanahan and Folkman 
1996). This is done by activating the angiogenic switch by changing the balance of 
angiogenesis inducers and countervailing inhibitors, increasing the expression of pro-
angiogenic factors like the vascular endothelial growth factor, VEGF, or reducing the 
expression of anti-angiogenic factors like thrombospondin-1 (Volpert, Dameron, and Bouck 
1997;Singh et al. 1995).
Although cancer cells are able to regulate angiogenesis, the blood vessels they develop are 
aberrant and have poor blood flow. Tumors therefore often become hypoxic (Harris 2002), 
and cells that do not manage to adapt to oxygen and nutrient deprivation undergo cell death 
by apoptosis, necrosis, and/or autophagy (Zhou et al. 2006). Tumor cells mostly respond to 
reduced oxygen levels through activation of hypoxia inducible factors (HIFs), although the 
responses may also be HIF-independent (Harris 2002). Paradoxically, hypoxia can also 
affect tumor growth positively by inducing genetic and adaptive changes (Zhou et al. 2006). 
This will allow the cancer cells to survive and proliferate in a hypoxic environment, 
resulting in a more aggressive and treatment resistant tumor phenotype. 
Tissue invasion and metastasis is a capability of cancer cells to move out from the primary 
tumor mass, invade adjacent tissues, and travel to distant sites where they settle down and 
found new colonies, called metastases. This is partly achieved through alteration of proteins 
involved in the tethering of cells to their surroundings in a tissue, including cell adhesion 
molecules (CAMs) and members of the immunoglobulin, cadherin, and integrin families. 
Energy metabolism is required at a high rate in cancer cells due to increased proliferation 
rate and the motile nature of cancer cells, resulting in the lack of oxygen and nutrition 
(Furuta et al. 2010). Persistent glucose metabolism and generation of lactate is therefore 
thought to be an adaptation of tumor cells to hypoxia. Alteration in the expression of genes 
involved in metabolic pathways like glycolysis and lipogenesis, contribute to the 
progression of tumor cells to become more aggressive phenotypes. Transformed cells are 
distinguished from normal cells in the constitutive activation of growth factor signaling 
pathways, which directly control cellular metabolism (Yalcin et al. 2009). 
Endocytosis is the process by which cells absorb molecules from outside the cell by 
engulfing them with their plasma membrane. A mechanism shared by tumor-initiating and 
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metastasizing cells is an aberrant tendency to disassemble signaling and adhesion complexes 
and sort them for either degradation or re-assembly, following vesicular trafficking 
(Mosesson, Mills, and Yarden 2008). Aberrant endocytosis thereby contributes to malignant 
transformation and is therefore looked upon as a crucial target of the processes driving 
cancer initiation and progression.
Clinical consequences of genetic alterations 
The biological tumor characteristics caused by genetic alterations promote aggressive 
phenotypes and may, in turn, lead to chemoradioresistance and poor clinical outcome.  
Radiotherapy and some types of chemotherapy cause damage of the DNA. The most serious 
DNA damage induced by radiation is DNA double-strand breaks, whereas 
chemotherapeutics like cisplatin, causes cross-linking of DNA (Borst, Rottenberg, and 
Jonkers 2008). In cervical cancer treatment, cisplatin is used in small doses in combination 
with radiotherapy to increase the cells sensitivity to radiation. However, the benefit of 
cisplatin is minor (Sundfor et al. 1996) and radiotherapy is therefore the most significant 
treatment for achieving local tumor control.  
DNA damage caused by radiotherapy initiates several cellular responses, like inducing cell 
cycle arrest, promoting apoptosis or mitotic catastrophe, initiating DNA repair, and stopping 
transcription (Huerta, Gao, and Saha 2009;Sakata et al. 2007). Tumors can develop 
resistance to radiotherapy by deregulation of cell cycle, by evasion of apoptosis, or by 
adaptation to hypoxia.
Cell cycle delay or arrest occurs after exposure to radiation due to the activation of cell-
cycle checkpoints (Kastan and Bartek 2004). When the check points are functional, they 
block further proliferation of the cells and suppress cancer development. In tumor cells, 
however, the checkpoints are often disabled because of genetic changes in cell cycle control 
genes like TP53 or BRCA1, resulting in loss of apoptotic mechanisms during progression. 
Also tumors that retain a functional TP53 pathway still frequently lose the basic apoptotic 
mechanisms and acquire resistance to apoptosis (Igney and Krammer 2002). This is 
probably due to enhanced expression of anti-apoptotic genes like BCL2 or inactivation of 
pro-apoptotic genes like BAX and APAF1. Mitotic catastrophe is therefore the major cell 
death mechanism following radiation therapy (Eriksson and Stigbrand 2010). This is a 
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delayed type of cell death executed days after treatment initiation, and may be induced 
either as a consequence of DNA damage and deficient cell cycle checkpoints or through 
hyperamplification of centrosomes (Eriksson et al. 2007;Kawamura et al. 2004).
Hypoxia leads to resistance to both chemo- and radiotherapy. Cells in a hypoxic 
environment harbor a range of genetic changes that make them more invasive, more likely 
to metastasize, and eventually harder to treat. Moreover, hypoxia increases radioresistance 
due to the requirement of oxygen during irradiation to produce maximal DNA damage 
through the creation of free radicals (Koch, Kruuv, and Frey 1973). It has been shown that 
severely hypoxic cells require a 2-3 fold higher dose of radiation to achieve the same level 
of cell killing compared to well-oxygenated cells (Karar and Maity 2009). Hypoxic cells 
have also been found to be resistant to chemotherapy, possibly because drugs do not 
penetrate into regions with low vascularity, because the cells are slowed in their progression 
through cell cycle, or because of difficulties in the uptake and metabolism of drugs by 
hypoxic cells (Moulder and Rockwell 1987;Kennedy et al. 1980).
Microarray technology 
For the past two decades, the development of genomic technology has revolutionized 
modern biological research (Chen, Jorgenson, and Cheung 2009). Genome wide analyses 
have made it possible for biologists to analyze genetic events on a global scale, and they 
have been used in gene discovery, biomarker determination, drug target identification and 
disease classification, as well as in understanding carcinogenesis. One of the genomic tools 
for high-throughput and large-scale genomic analysis is microarray technology. This 
technology allows the simultaneous analysis of thousands of variables in a single sample in 
a simple hybridization experiment (Jares 2006).  
Microarrays were first described in 1995 and were originally designed for depositing DNA 
onto solid support for gene expression profiling (Schena et al. 1995). Since then, the 
technology has been extended to DNA copy number analysis (Pinkel et al. 1998;Snijders et 
al. 2001), protein measurements (Kingsmore 2006), microRNA analysis (Yin, Zhao, and 
Morris 2008), SNP genotyping (Gunderson et al. 2005), DNA methylation profiling (van 
and Henikoff 2003), and protein-DNA interactions and chromatin modifications using 
ChiIP-microarrays (Buck and Lieb 2004). In cancer research, the technology has resulted in 
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numerous of novel opportunities, for example detailed genomic comparison of different 
tumor types, discovery of novel aberrant chromosomal regions, and sub-classification of 
tumors according to differences in their gene expression (Rew 2001). Microarrays have also 
offered new approaches to drug development and therapeutic efficacy, for example by 
characterizing each cell, tissue, and tumor in terms of the mechanism of drug action, its 
predicted drug sensitivity, and side-effect profile to a number of reagents. These novel 
opportunities have aimed in understanding the initiation and development of the disease.  
Principle 
DNA microarrays consist of a solid matrix where thousands of known nucleic acid 
fragments (BACs, cDNAs, oligonucleotides) which constitute the microarray probes, are 
synthesized or spotted to a glass support (Jares 2006). The principle of DNA microarrays 
relies on the ability of single-strand nucleic acid fragments to hybridize with high specificity 
to a second complementary single strand to generate a double-stranded DNA molecule (Fig. 
7). The sample or target is labeled by using either radioactivity or fluorescent dyes and 
hybridized to the array surface. After stringency washes have been performed, the 
complementary target-probe complexes remain tightly bound and the amount of the retained 
labeled target is quantified by fluorescent detector systems, followed by a data analysis 
process.
Fig. 7: The principle of two-channel microarray technology 
Platforms
The microarray probes are large-insert clones like bacterial artificial chromosomes (BACs) 
(150-350 kb), P1-derived artificial chromosomes (PACs) (100-300 kb), formid clones (40 
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kb), cosmid clones (37-52 kb), smaller insert clones (1.5-4.5 kb), cDNA clones (0.5-2 kb), 
genomic PCR products (100 bp-1.5 kb), and oligonucleotides (25-80 bp). BACs are used for 
DNA copy number detection and provide the most comprehensive coverage of the genome 
as well as producing robust hybridizations with low noise. However, the resolution is 
generally only about 1 Mb and it is difficult to identify single copy number differences 
smaller than 50 kb (Carter 2007). Oligonucleotides provide the highest potential resolution 
for array CGH, with the possibility of achieving more than 2 million oligonucleotides per 
array (NimbleGen, WI). For gene expression analysis, the two most common spotted arrays 
are cDNA microarrays and oligo-based arrays. 
Alternatives to the in-house produced arrays are commercial microarray platforms. The 
most common platform is the GeneChip system from Affymetrix (Santa Clara, CA). 
GeneChips are made by synthesizing matched sets of short oligonucleotide pairs, one that 
matches perfectly and one with a single mismatch, on a silicon-based substrate using a 
photolithographic process (Ness 2007;Pease et al. 1994). Other common platforms are 
Agilent (Santa Clara, CA) and Illumina (San Diego, CA). Agilent arrays are synthesized 
following the same principles as Affymetrix, whereas Illumina uses designed 
oligonucleotide probes attached to beads that are deposited randomly in a support. These are 
created by either impregnating beads with different concentrations of fluorescent dye, or by 
some type of barcoding technology. The beads are addressable and used to identify specific 
binding events that occur on their surface.  
Array comparative genomic hybridization 
CGH has been widely used as a genome-wide screening method to search for DNA copy 
numbers (Kallioniemi et al. 1992). The first approach was introduced in 1992, where total 
genomic DNA from a test and a reference cell population were co-hybridized to normal 
metaphase chromosomes. This limited the detection of events involving small regions of the 
genome, and the resolution was only of about 5-10 Mb (Carter 2007). The limitation has 
been resolved by the introduction of microarrays in the late 1990s (Pinkel et al.
1998;Solinas-Toldo et al. 1997). aCGH combines microarray technology with the CGH 
approach and the metaphase chromosomes have been replaced by defined nucleic acid 
fragments. The resolution is therefore limited only by the number, distribution and the 
length of the sequences spotted onto the array. A higher resolution allows a precise mapping 
of the boundaries of the detected genomic rearrangements.  
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Limitations in clinical applications of aCGH 
Despite the improvements in the aCGH technique in the last decade, only relative copy 
numbers have been achieved. Absolute copy numbers have only been obtained on a single 
gene basis using fluorescence in situ hybridization (FISH). This may cause problems when 
using aCGH for analysis of clinical samples. The relative values are influenced by the 
ploidy, the normal cell fraction in the sample, the experimental bias, and the DNA copy 
numbers (Pinkel and Albertson 2005). The tumor ploidy and normal cell content often vary 
considerably among the samples, making comparison across the tumors unreliable. This is 
also the case for the intratumor heterogeneity in the DNA copy numbers of some tumors.  
Different approaches to correct for the confounding effect caused by the normal cell content 
of the samples have been attempted, such as excluding these samples from the analysis or 
handling them separately (Weir et al. 2007), correcting the ratio levels based on histological 
examinations of the tumor sections (Chin et al. 2007), or reducing the normal cell fraction 
using laser capture microdissection (Hunt and Finkelstein 2004). Corrections based on 
histological examinations are not satisfactory since a different part of the biopsy is used, 
whereas microdissection is often expensive, difficult to perform, and time consuming. This 
has led to difficulties in interpreting the data and limited the clinical usefulness of the 
technique.
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Summary of papers 
Paper I: GeneCount: genome-wide calculation of absolute tumor DNA copy numbers 
from array comparative genomic hybridization data 
In this paper, GeneCount is presented, a method for genome-wide calculation of absolute 
DNA copy numbers from clinical aCGH data. GeneCount estimates and corrects for the 
proportion of normal cells in the samples, corrects for tumor ploidy, and considers possible 
intratumor heterogeneity in DNA copy numbers. Inputs to the model are tumor ploidy, 
experimental bias, and aCGH ratios. Predetermined measures of tumor ploidy and 
experimental bias are therefore needed. The absolute DNA copy numbers were compared 
with FISH data and showed 97% consistency. The data were used to generate gene dosage 
(copy number/ploidy) profiles that could be compared across patients regardless of ploidy 
and normal cell content. Significant improvements compared to existing methods for 
exploring gene dosages in cancers were demonstrated. In particular, we showed a higher 
sensitivity in the detection of cervical tumors with copy number changes. GeneCount was 
implemented in software packages to be used downstream of statistical methods for 
breakpoint detection, like GLAD and CGH-Explorer.  
Paper II: Gene dosage, expression and ontology analysis identifies driver genes in the 
carcinogenesis and chemoradioresistance of cervical cancer
Integrative analysis of gene dosage, expression, and ontology (GO) data was performed to 
discover driver genes in the carcinogenesis and chemoradioresistance of cervical cancers. 
Microarray techniques were used to generate gene dosage and expression profiles of 102 
patients. Twenty-nine recurrent gains and losses and 3 losses (on 3p, 13q, 21q) associated 
with poor outcome after chemoradiotherapy were identified. The 3 predictive regions 
showed low intratumor heterogeneity, indicating that they had emerged prior to many other 
alterations and probably were early events in carcinogenesis. The genetic alterations were 
correlated with gene expression, which identified the genes regulated by the alterations. 
Correlation with GO data resulted in five biological processes; apoptosis, metabolism, 
macromolecule localization, translation, and transcription, that were overrepresented among 
the gene dosage regulated genes. Four genes on 3p (RYBP, GBE1) and 13q (FAM48A,
MED4) correlated with survival at the gene dosage and expression level and were 
satisfactorily validated in the independent cohort. Fifty-seven candidate driver genes of 24 
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genetic events were identified by these integrated analyses, including novel loci responsible 
for chemoradioresistance. Further mapping of the connections among genetic events, 
drivers, and biological processes suggested that each individual event stimulates specific 
processes in carcinogenesis through the coordinated control of multiple genes. These results 
show that genetic alterations play a significant role in carcinogenesis, and may provide 
novel therapeutic opportunities of both early and advanced stage cervical cancers. 
Paper III: Microarray based analyses of gene expression and pathways associated with 
loss on chromosome 3p in cervical cancer  
In this paper, microarray data was used for identification of genes and pathways affected by 
the frequent loss on chromosome 3p in cervical cancer. Pretreatment tumor samples from 
160 cervical cancer patients who received chemoradiotherapy were included. Pairwise gene 
dosage (aCGH) and expression (Illumina beadarrays) analysis in 77 patients identified 
candidate target genes of the 3p loss. Gene expressions associated with the 3p loss were 
subjected to pathway, gene ontology, and gene set analyses. Protein expression was assessed 
by immunohistochemistry in 150 patients and cervical cancer cell lines. Loss of 3p11.2-
p14.2 was the most frequent 3p event and was associated with poor clinical outcome. 
Fourteen candidate targets of the loss were identified within the region, and three of the 
genes, RYBP, TMF1, and PSMD6, generated large networks of interaction partners 
differentially expressed between patients with and without 3p loss. Apoptosis (RYBP) and 
cellular metabolism (TMF1, PSMD6) were the biological processes overrepresented in the 
networks. Gene set analysis showed that the pro-apoptotic gene set, involving several genes 
in the RYBP network, was downregulated in patients with 3p loss. Nuclear RYBP protein 
expression was found to be downregulated in tumors with 3p loss and was also associated 
with clinical outcome in stage 1 and 2 cancers (p=0.034). These results indicate that 
multiple target genes and their interaction partners are affected by the frequent 3p11.2-p14.2 
loss in cervical cancer. Repression of one of these genes, RYBP, leads to evasion of 
apoptosis and disease progression.
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Experimental considerations 
Patients
The tumor material used in these studies was collected at the Norwegian Radium Hospital 
since 2001. The clinical protocol was approved by the regional ethical committee and 
informed consent was obtained from all patients. The samples were obtained from the 
primary tumors at the time of diagnosis and made anonymous by using a letter code 
followed by inclusion number. One to four biopsies were taken from different locations of 
the tumor, and for the microarray experiments, the biopsies were pooled. Squamous cell 
carcinoma, adenosquamous carcinoma, and adenocarcinoma were included in paper I and II, 
whereas paper III only included the squamous cell carcinomas. In paper II and III, only 
patients who received curative radiotherapy were included, involving tumors with stage 1b-
4a, whereas paper I also included stage 4b.
There are several strengths of this tumor material. First, up to 156 tumor samples were 
included, making the statistical analysis more reliable in comparison to other studies with 
less samples. Second, all the patients received the same treatment, contributing to a more 
homogenous patient group, which reduces confounding effects caused by variation in 
efficiency of different treatments. Third, the long observation time ensured that most 
failures already had been detected, and fourth, up to four biopsies were pooled from each 
tumor, accounting for the possible intratumor heterogeneity of the samples. 
A limitation of this tumor material is that in paper I and II, patients with different histology 
were included. This may have influenced the biological findings of paper II, since tumors 
with different histology might show distinct patterns of gains and losses. This was, however, 
accounted for in the supplementary material of the paper. In paper I, the difference in 
histology did not play a significant role, due to the methodological character of the study. 
25
Microarray techniques 
aCGH
BAC-arrays were used for the aCGH experiments (papers I-III). These arrays cover the 
whole genome and provide a high signal to noise ratio compared to oligoarrays, increasing 
the reliability of the data. The resolution of BAC-arrays is, however, limited. Moreover, 
only the average gene dosage of each DNA segment is obtained, and each segment may 
cover several genes. This may result in undetected gains and losses if the alterations involve 
short DNA segments. On the other hand, in cervical cancer, most gains and losses seem to 
include large chromosomal regions like the whole p- or q-arm (Wilting et al. 2008), 
resulting in the detection of most alterations although the start and stop positions may be 
inaccurate. Furthermore, in paper II and III we focused on chromosomal gains and losses 
with altered expression of the corresponding genes, increasing the reliability of the detected 
copy number changes.    
Gene expression arrays 
In paper I and II, cDNA expression arrays were used. These arrays do not cover the whole 
genome, incorrect annotation is often encountered, and for genes with different isoforms, an 
average expression value is given. Illumina gene expression bead arrays include all genes in 
the genome, provide separate data for most isoforms, and thereby give more accurate 
results. This technique was therefore applied in paper III and for validation in paper II.
Downstream analysis of microarray data 
Instead of looking at individual genes, methods such as Network Analysis, Gene Ontology 
(GO) analysis, and Significant Analysis of Microarrays for Gene Sets (SAM-GS) take 
whole gene sets into account, incorporating biological knowledge regarding gene function 
and how genes work together. Analyses like these are useful when working with datasets 
containing a large number of genes.  
Network Analysis allows genes to generate a network of their protein interactions from an 
integrated set of protein interaction databases (Stark et al. 2006;Keshava Prasad et al.
2009;Kerrien et al. 2007). In this work, we selected the genes that were differentially 
expressed between patients with and without 3p-loss, and generated second degree of 
interaction networks for the 3p genes that were significantly regulated by gene dosage. In 
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this way, we could provide evidences that several interaction partners of the candidate target 
genes RYBP, TMF1, and PSMD6 were deregulated in tumors with 3p-loss. 
GO is a collection of controlled vocabularies; molecular function, cellular component, and 
biological process, describing the biology of a gene product in any organism. The GO 
categories of two or more gene lists can be compared with statistical tests. eGOn (explore 
Gene Ontology) is a tool that can be used to annotate, display, and perform statistical 
hypothesis testing to assess the degree of similarity of GO categories between different gene 
lists (Beisvag et al. 2006). eGOn has advantages over other annotation databases in that it 
enables filtering of annotations by evidence code, it allows the entry of new annotations, 
and it provides a series of robust, statistical tests that are thoroughly validated and 
documented. In paper II, we used the eGOn to identify biological processes that were 
associated with the recurrent and predictive gene dosage alterations. These biological 
processes were closely related to known cancer hallmarks, and by using eGOn, we therefore 
provided evidences that genetic alterations lead to carcinogenesis. In paper III, eGOn was 
used to identify biological processes that were associated with the interaction networks of 
RYBP, TMF1, and PSMD6, pointing to the phenotypes resulting from the 3p-loss.   
SAM-GS determines whether a defined set of genes shows statistically significant, 
concordant differences between two biological states (Liu et al. 2007;Dinu et al. 2007). 
Testing gene sets rather than genes moves the analysis towards biological themes, thus 
accelerating the discovery process. Further, the number of tests is reduced and thereby the 
multiple testing concerns. SAM-GS considers all of the genes in an experiment, not only the 
genes above an arbitrary cutoff in terms of fold-change or significance. In this work, SAM-
GS showed that the pro-apoptotic signaling pathway was significantly downregulated in 
tumors with 3p-loss.  
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Discussion
Tool for DNA copy number determination in cervical cancers 
GeneCount was developed to enable genome-wide calculation of absolute DNA copy 
numbers from clinical aCGH data. This method corrects for the normal cell fraction and 
tumor ploidy, and considers intratumor heterogeneity in DNA copy numbers, making it 
highly valuable when working with tumor samples. Especially cervical cancers show a high 
frequency of aneuploidy and by correcting for this and the normal cell content, GeneCount 
enabled reliable comparisons across experiments, as demonstrated in paper II and III. 
The importance of taking tumor ploidy, normal cell content, and the genetic intratumor 
heterogeneity into account in analysis of aCGH data has also been noticed by others, and 
several statistical methods dealing with these aspects have later been developed. The 
ASCAT algorithm dissects allelic-specific copy numbers from SNP arrays (Van et al.
2010). A mathematical modeling approach is applied to estimate both the normal cell 
content and the tumor ploidy, which are utilized in the calculation of the copy numbers. A 
similar approach has also been proposed by Yau and colleagues (Yau et al. 2010).
To obtain absolute copy numbers by GeneCount, predetermination of tumor ploidy is 
required. This was performed by flow cytometric analysis, which is highly accurate in 
determining the ploidy. The mathematical models mentioned above estimate the tumor 
ploidy in addition to copy numbers and normal cell content. GeneCount may therefore result 
in more accurate copy numbers since fewer parameters have to be modeled. Allelic specific 
data achieved from SNP arrays are useful, and only minor modifications of GeneCount are 
required to use this method on the same SNP arrays.   
Some of the new methods have also considered the intratumor heterogeneity in the copy 
number changes. Both Yau and colleagues (Yau et al. 2010) and Letouzé and colleagues 
(Letouze et al. 2010) have developed statistical methods that attempt to tackle intratumor 
heterogeneity. These methods may have advantages over GeneCount in that they are made 
for SNP arrays, which have high resolution. Even though GeneCount can be used to 
determine absolute DNA copy numbers from SNP arrays, tests need to be carried out to see 
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whether the signal-to-noise ratio of these arrays is satisfactory for determining heterogeneity 
in the copy numbers by GeneCount.   
DNA copy number alterations in carcinogenesis 
Until now, the overall importance of copy number alterations in cervical carcinogenesis and 
their relationship to known cancer hallmarks have remained unknown. In paper II we 
demonstrated how the recurrent gains and losses in cervical carcinoma were affecting the 
expression of certain genes that, in turn, were associated with five biological processes: 
apoptosis, metabolism, macromolecule localization, translation, and transcription. These 
processes were closely related to the known cancer hallmarks; evasion of apoptosis, 
metabolism and endocytosis. This was further supported by the findings in paper III, where 
candidate target genes of the loss on 3p were involved in apoptosis and cellular metabolism, 
indicating an association between the 3p-loss and the biological processes. This work 
therefore indicates that DNA copy number alterations play a significant role in reaching the 
hallmarks of cancer and thereby promote carcinogenesis in cervical cancer. The importance 
of copy number alterations for evasion of apoptosis in cervical cancer has also been 
demonstrated by Imoto and colleagues (Imoto et al. 2002). They showed that amplification 
of 11q21-q23 correlated with overexpression of the antiapoptotic gene BIRC2, resistance to 
apoptosis, and poor survival after radiotherapy.
To explore whether the recurrent genetic alterations were early or late events in 
carcinogenesis, the heterogeneity analysis in GeneCount was used. The recurrent alterations 
seemed to be early events since they showed minor intratumor heterogeneity compared to 
the other genetic alterations. This indicates that the hallmarks associated with these 
alterations arise early in the carcinogenesis and may be candidate biomarkers also in early 
stages of the disease. The more heterogeneous alterations, which arise later in the 
carcinogenesis, may either be associated with other hallmarks or they may be associated 
with the same hallmarks as the earlier events, reinforcing their effect and providing the 
tumor with alternative strategies to progress. 
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DNA copy number alterations and chemoradioresistance 
In paper II it was shown that loss on 3p, 13q, and 21q were associated with 
chemoradioresistance. As mentioned earlier, tumors can develop resistance to radiotherapy 
by deregulation of cell cycle, evasion of apoptosis, or adaptation to hypoxia. In paper III it 
was suggested that loss of RYBP led to downregulation of other pro-apoptotic genes, and 
thereby evasion of apoptosis, which may have promoted chemoradioresistance and a more 
aggressive phenotype. Hence, a poorer clinical outcome was observed for patients with 
RYBP downregulation. Neither of the other 14 gene dosage regulated genes on 3p in paper 
III have been directly associated with any of the known biological processes leading to 
chemoradioresistance. A few of the genes, such as FOXP1, GBE1, LRIG1, RYBP, TMF1,
and SHQ1 have, however, shown reduced expression in different types of cancer, and have 
therefore been implicated as potential tumor suppressor genes. 
The target genes on 13q and 21q are still unknown, and therefore also the mechanisms of 
their association to the clinical outcome. Two candidates on 13q, MED4 and FAM48A, were 
suggested in paper II, but their potential role in chemoradioresistance is not clear. FAM48A
is known to be required for activation of the MAPK p38 pathway, which represses cell 
proliferation, and may therefore be involved in deregulation of cell cycle, whereas loss of 
MED4 may impair transcription of genes with anti-cancer effect. However, the use of cDNA 
expression arrays in paper II limited the number of genes included, and the targets of the 
alterations may not have been included in the data set. More studies are therefore needed to 
determine the target genes of 13q and 21q and their role in chemoradioresistance.
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Future perspectives 
Implementation in the clinic 
Biomarkers can either be used in diagnosis to select patients for different treatment 
strategies, or in development of targeted therapeutics to improve the effect of the standard 
radiation treatment. This work proposes novel candidate biomarkers that may be used 
clinically, both in diagnosis and in therapy. To implement the candidate biomarkers in the 
cervical cancer clinic, stringent clinical and biological validation is needed (Chin and Gray 
2008).
Diagnosis   
Before the DNA copy numbers, gene expression or protein expression can be used for risk 
stratification and therapy decision, clinical validation in independent patient groups is 
needed to ensure reproducibility. This should preferably be carried out using multicenter 
trials. Multicenter trials have the benefits of recruiting a large number of patients at different 
geographic locations, enabling the inclusion of a wider range of population groups and the 
ability to compare results among different medical institutions. This will increase the 
generalizability, since significant variations between population groups with different 
genetic and environmental background may exist. Successful validation of the biomarkers 
proposed in this work, would be an important step towards implementing the copy number 
alterations on 3p, 13q, or 21q, RYBP gene expression, or RYBP protein expression as 
predictive, diagnostic biomarkers in cervical cancer. By adopting similar strategies on 13q 
and 21q as was used on 3p to find the target genes, even more biomarkers at the 
gene/protein expression level could be candidates for implementation. All three levels could 
potentially be used, but alterations at the DNA level might have the largest potential as 
biomarkers due to the stability of copy number alterations. Moreover, even though the three 
genomic alterations could be used separately, paper II suggests that it is more to gain if 
information about all three regions is combined. To date, no diagnostic biomarkers exist for 
cervical cancer, but other cancer types, like breast cancer, have the benefit of using for 
example the amplification of the HER2 gene, to predict the response to trastuzumab and 
lapatinib (Esteva et al. 2010).
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Therapy 
To use biomarkers in therapy, pre-clinical and clinical trials are required to collect safety 
and efficacy data for health interventions. A better understanding of the gene or protein 
function and the effect of manipulation is also needed. Pre-clinical trials, starting with in 
vitro studies and continuing with in vivo studies on animal models, form a major part of the 
biological validation and are necessary before starting the clinical trials (Chin and Gray 
2008;Yap et al. 2010). All phases of clinical trials will normally be carried out, starting with 
obtaining information regarding efficacy and toxicity, then assessing safety, tolerability, and 
how well the drug works. Finally, randomized, controlled multicenter trials on large patient 
groups have to be completed.  
Targeting oncogenes can be accomplished by inhibition of oncogene transcription, reduction 
of mRNA translation, or by interference with oncoprotein interactions, transportation, and 
function (Hughes 2004). In this work, however, the candidate biomarkers have tumor 
suppressor function, and mechanisms for targeting suppressor genes are often more 
complicated. One strategy is to restore gene expression using adenoviral vectors. This has 
been tested in tumor cell lines for several tumor suppressor genes, including RYBP (Novak 
and Phillips 2008). Infecting cells with a generated adenovirus expressing RYBP resulted in 
induction of apoptosis. The effect was seen only in tumor cell lines, whereas normal cells 
were unaffected, suggesting that RYBP has a potential as a cancer gene therapy agent 
(Danen-van Oorschot et al. 2004).
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Abstract
Absolute tumor DNA copy numbers can currently be achieved only on a single gene basis by using
fluorescence in situ hybridization (FISH). We present GeneCount, a method for genome-wide
calculation of absolute copy numbers from clinical array comparative genomic hybridization data.
The tumor cell fraction is reliably estimated in the model. Data consistent with FISH results are
achieved. We demonstrate significant improvements over existing methods for exploring gene
dosages and intratumor copy number heterogeneity in cancers.
Background
Array comparative genomic hybridization (aCGH) is widely
used for genome-wide mapping of DNA copy number
changes in malignant cells [1,2]. Genetic gains and losses
impact gene expression levels, and thereby promote tumor
growth and progression [3-5]. Numerous clinical studies have
been performed to find tumor characteristics and to classify
patients with respect to their prognosis based on the copy
number changes [6,7]. The usefulness of the aCGH data is
limited, however, because only relative and not absolute copy
numbers are achieved, making the interpretation of the data
and comparisons across experiments difficult. Absolute DNA
copy numbers can be obtained only on a single gene basis by
the use of fluorescence in situ hybridization (FISH). Develop-
ment of genome-wide methods for this purpose would enable
generation of universal gene copy number databases of indi-
vidual diseases that could be utilized more widely, as is the
goal of several public repositories like the Mitelman Database
of Chromosome Aberrations in Cancer [8].
The relative values achieved in aCGH experiments are influ-
enced by the total DNA content (ploidy) of the tumor cells, the
proportion of normal cells in the sample, and the experimen-
tal bias, in addition to the DNA copy numbers. The values are
presented as intensity ratios between tumor and normal DNA
[2]. The data are normalized so that the ratio of 1.0 is the
baseline for the analysis, and corresponds to two DNA copies
in near diploid (2n) tumors. The copy number changes are
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identified from the ratios deviating from the baseline, using
statistical methods for ratio smoothing and breakpoint detec-
tion [9-12]. To assign an absolute copy number to each ratio
level identified by the statistical analysis and thereby score
genetic aberrations are, however, challenging. In aneuploid
tumors with gross alterations in the DNA content, the base-
line represents a copy number other than 2, like 3 or 4 in tri-
or tetraploid tumors, or a non-integer value when the DNA
content differs from n, 2n, 3n, ... mn [13]. The presence of
normal cells within the sample and experimental bias reduce
the ratio dynamics. Moreover, in many tumors, several sub-
populations of malignant cells with different genetic charac-
teristics exist, leading to intratumor heterogeneity in the DNA
copy numbers [14-16] and increased complexity in the data.
Unreliable results occur, therefore, when common ratio levels
are used to score gains and losses in tumors with different
ploidy and normal cell content.
The confounding effect caused by normal cells within tumor
samples is recognized as a problem in aCGH analyses and has
been handled by excluding low purity samples [17,18] or cor-
recting the ratio levels based on histological examination of
tumor sections [6]. The latter approach is not satisfactory
because only the proportion of connective tissue surrounding
the tumor parenchyma, and not the infiltrating immune cells,
is precisely quantified. Moreover, the measurements cannot
be performed on exactly the same tissue as used in the aCGH
experiment and may, therefore, not be representative. A
model including the CGH ratios, ploidy, and experimental
bias has been proposed for estimation of absolute DNA copy
numbers in tumor cell lines [19]. To our knowledge, no
method exists that also considers the normal cell content and,
thus, is suited for analyses of clinical tumor samples.
We here present a new model, GeneCount, where the propor-
tion of normal cells is estimated and corrected for and possi-
ble intratumor heterogeneity in DNA copy numbers is
considered. Inputs to our model are the DNA index (DI,
where DI = 1/2·tumor ploidy), tumor cell fraction, experi-
mental bias, and aCGH ratios. Predetermined measures of
tumor ploidy, determined either by flow or image based
cytometry, are needed. The tumor cell fraction can be deter-
mined by, for example, flow cytometry on the same part of the
sample as used in the aCGH experiment. In cases of unknown
normal cell content, the tumor cell fraction is estimated in the
model. The experimental bias is determined from the X-chro-
mosome ratio in aCGH experiments where male and female
DNA is compared. Smoothed ratio levels from any existing
statistical analysis tools for breakpoint detection can be used.
We show that the model enabled automatic and genome-wide
calculation of DNA copy numbers from aCGH data of both
hematopoietic and solid tumors. The feasibility of GeneCount
was demonstrated by analysis of 94 lymphomas, for which
the DNA index and tumor cell fraction had been determined
by use of flow cytometry and an extensive exploration of DNA
copy numbers had been performed by the use of FISH in pre-
vious studies [20-25]. The GeneCount results, both based on
the pre-determined tumor cell fraction and that determined
by the model, were compared with the FISH data of 362 genes
with and without gains and losses, showing 97% consistency
in both cases. In particular, we explored the copy numbers
achieved in the t(14;18) translocated chromosomal region
involving BCL2. We further demonstrated the potential of
GeneCount in analysis of solid tumors without pre-deter-
mined tumor cell fractions by relating the copy number of
selected genes in 93 cervical cancers to gene expression and
treatment outcome. By use of GeneCount we obtained a
higher sensitivity in detecting cervix tumors with copy
number changes than was obtained in analysis based directly
on the ratio levels. Finally, we identified intratumor heteroge-
neity of DNA copy numbers in the lymphomas and cervical
cancers, and showed how this information could be used to
draw conclusions about the evolution of the genetic aberra-
tions in the tumors. GeneCount was implemented in a soft-
ware package to be used downstream of statistical methods
for breakpoint detection, and results based on both the GLAD
and CGH-Explorer packages are presented [9,11]. We supply
our method through the open-source and free web-based
database BioArray Software Environment (BASE) [26].
Results
Basis of GeneCount
Our model utilizes the fact that the normalized aCGH ratio
increases with increasing DNA copy number in a stepwise
manner, where the step size is dependent on the DI, the
tumor cell fraction, and the experimental bias (Figure 1). In
near diploid tumors (DI = 1) without a contribution from nor-
mal cells or affected by experimental bias, an increment of 1
in the copy number increases the ratio by a value of 0.5, lead-
ing to a normalized ratio of 0.5, 1, 1.5, 2, and so on (-1, 0, 0.69,
1 on a log2 scale) for a copy number of 1, 2, 3, and 4, respec-
tively (see Equation 2 in Materials and methods). The corre-
sponding increase in tetraploid tumors (DI = 2) is 0.25,
whereas an increase between 0.25 and 0.5 occurs in tumors
with a DI between 1 and 2. Baseline, at a log2 ratio of 0, corre-
sponds to 2, 3, and 4 DNA copies in near diploid (Figure 1a),
triploid, and tetraploid (Figure 1b) tumors, respectively. For
DIs between 1 and 1.5 or between 1.5 and 2, baseline repre-
sents a copy number between 2 and 3 (Figure 1c) or between
3 and 4. The presence of normal cells within the tumor sam-
ple reduces the increase in aCGH ratio with incremental copy
number (Equation 3), as can be seen when comparing the
ratios of two near diploid lymphomas with different tumor
cell fractions (Figures 1a,d). Using common ratio levels for
scoring gains and losses in tumors like those presented in Fig-
ures 1a-d leads, therefore, to different results with respect to
copy number changes.
A further reduction in the ratio dynamics occurs due to exper-
imental bias (Equation 4). The bias, as represented by the
http://genomebiology.com/2008/9/5/R86 Genome Biology 2008,     Volume 9, Issue 5, Article R86       Lyng et al. R86.3
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Figure 1 (see legend on following page)
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dynamic factor, q, can be determined from control experi-
ments, where normal DNA from males and females is cohy-
bridized (Figure 1e). Theoretically, the X-chromosome ratio is
0.5 (-1 on a log2 scale), but the experimental bias reduces the
ratio dynamics, leading to a ratio level closer to zero. The
absolute value of the log2-transformed ratio level was used as
a measure of q (Figure 1e). This value differed little among the
slide series used here, ranging from 0.75-0.85 with a mean ±
standard deviation of 0.80 ± 0.04 based on 8 control experi-
ments. A q-value of 0.8 and range of 0.7-0.9 was used in the
GeneCount calculations in the cases of known and unknown
tumor cell fraction, respectively.
To enable automatic calculation of the copy number associ-
ated with each array probe, we implemented GeneCount in a
program to be run on top of statistical analysis packages for
aCGH ratio smoothing and breakpoint detection (Additional
data file 1). A separate algorithm was developed for samples
with unknown tumor cell fraction, where the fraction was
estimated based on two ratio levels and DI (panel B in Addi-
tional data file 1), as described in Materials and methods. One
decimal was included in the calculated DNA copy numbers
when evaluating the results in comparison with FISH data.
Otherwise, the numbers were rounded off to the nearest inte-
ger values.
GeneCount copy numbers in comparison with FISH 
data
We compared the GeneCount results of 94 lymphomas with
previously published FISH data from the same tumors [20-
25]. The FISH probes were located at chromosomal regions
with frequent copy number changes (Figure 1 and Additional
data file 2), and copy numbers within the range of 0-8 had
been measured. The DIs, ranging from 0.95-2.23, and the
tumor cell fractions, ranging from 27% to 98%, were used as
inputs to GeneCount, together with the smoothed aCGH
ratios from the GLAD and CGH-Explorer packages. CGH-
Explorer applied a more extensive ratio smoothing than
GLAD, and this led occasionally to differences in the ratio lev-
els and breakpoint detection between the two programs.
GeneCount with known tumor cell fraction
In most cases, we found an excellent agreement between the
DNA copy number determined by GeneCount and FISH,
Illustration of the stepwise increase in aCGH ratios with increasing DNA copy numberFigu e 1 (see previous  page)
Illustration of the stepwise increase in aCGH ratios with increasing DNA copy number. Frequency histograms (% array probes) of aCGH ratios (left 
panels) and plot of aCGH ratio versus chromosomal location (right panels) are shown for a lymphoma with a DNA index (DI) of (a) 1.02, (b) 1.94, (c) 
1.21, and (d) 1.05, and (e) for normal DNA comparing male and female. The tumor cell fraction, measured by flow cytometry, is indicated for each tumor. 
DNA copy numbers estimated by GeneCount are marked; those in black were consistent with FISH data, whereas those in red have not been subjected 
to FISH measurements in the specific tumors shown. The arrows in the right panels point to the locations of the FISH probes. At a DI close to 1 and 2 
(a,b,d,e) the ratio distribution shows a major peak at a median log2 value of approximately zero, representing the most frequent DNA copy numbers of 2 
and 4, respectively. At a DI of 1.21 (c) the baseline at a log2 ratio of 0 represents a number between 2 and 3 DNA copies. Note the smaller increase in the 
ratios with increasing DNA copy number at a tumor cell fraction of 70% (d) than of 96% (a). In (e), determination of the dynamic factor, q, as the absolute 
value of the X-chromosome log2 ratio level is indicated.
GeneCount calculations with known tumor cell fractionFigure 2
GeneCount calculations with known tumor cell fraction. DNA copy 
number calculated by GeneCount is plotted against the corresponding 
FISH result for 9 genes in 94 lymphomas. The smoothed aCGH ratios 
from (a) GLAD and (b) CGH-explorer, a q-value of 0.8, and a DI and 
tumor cell fraction determined by flow cytometry were inputs to 
GeneCount. Grey and blue columns represent GeneCount results that 
were consistent and inconsistent with the FISH data, respectively, after 
rounding off the GeneCount number to the nearest integer value. 
Frequency distributions are shown for each copy number, containing 1, 25, 
246, 66, 15, 5, 4, and 1 value at a FISH copy number of 0, 1, 2, 3, 4, 5, 6, 
and 8, respectively.
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regardless of whether GLAD or CGH-Explorer was used for
breakpoint detection (Figure 2). The correlation between the
data sets was considerably better than when the ratio levels
were used in the comparison (Additional data file 3). Based
on GLAD, 350 out of 362 GeneCount values were consistent
with the FISH data (97%), whereas the corresponding
number based on CGH-Explorer was 340 out of 362 (94%)
(Figure 2). The few discrepancies between the GeneCount
and FISH results occurred mainly for two reasons. First,
GLAD and/or CGH-Explorer failed to detect the ratio change
of some of the genes that had a copy number change by FISH
(panel A in Additional data file 4). Second, the ratio level, and
therefore the copy number, was inaccurately determined for
some aberrations involving only a few array probes (panel B
in Additional data file 4). This was primarily the case for aber-
rations with less than three probes, like the homozygote dele-
tion involving two probes that covered RB1 in one of the
tumors (FISH copy number of 0 in Figure 2 and panel B in
Additional data file 4). The discrepancies between the Gene-
Count and FISH data were related, therefore, to the software
used for breakpoint detection and not due to errors in the
GeneCount algorithm.
GeneCount with unknown tumor cell fraction
The tumor cell fraction could be estimated for 55 and 43 out
of 94 lymphomas based on GLAD and CGH-Explorer,
respectively. The remaining tumors lacked aberrations or two
different ratio levels that could be used for the estimation
(Materials and methods). The estimated tumor cell fractions
correlated significantly with those measured by flow cytome-
try (Figure 3). Moreover, the estimates had a coefficient of
variance (CV) of less than 11% (Figure 3), and were therefore
fairly stable. The mean q-value determined in the calculation
differed little across the tumors, ranging from 0.73-0.84
(GLAD) and 0.74-0.82 (CGH-Explorer) (data not shown).
The consistency between the GeneCount and FISH data (Fig-
ure 4) was comparable to when the known tumor cell fraction
was used (Figure 2) and much better than when the ratio lev-
els and FISH data were compared (Additional data file 3).
Based on GLAD, 218 out of 231 DNA copy numbers were in
agreement with the FISH data (94%), whereas the corre-
sponding numbers based on CGH-Explorer were 173 out of
179 (97%) (Figure 4). Most differences between the Gene-
Count and FISH results occurred for the same reasons as
when the known tumor cell fraction was used (Additional
data file 4). Additionally, a discrepancy was seen for some of
the highest copy numbers based on GLAD (Figure 4), due to a
large discrepancy between the estimated and measured
tumor cell fraction in one of the cases (Figure 3a).
DNA copy numbers in translocated chromosomal regions
The relationship between the GeneCount estimates and FISH
data in translocated chromosomal regions was explored by
using BCL2, which is involved in the translocation t(14;18) in
lymphomas, as an example. The aCGH probe covering BCL2
is located telomeric of the breakpoint. The aCGH data and
GeneCount results of BCL2 were therefore not affected by the
translocation. For FISH analysis, we selected a BCL2 probe
covering the breakpoint. The probe signal was split in tumors
with translocation, leading to a signal from both
der(14)t(14;18) and der(18)t(14;18), although BCL2 is located
on the former chromosome. The FISH signal was therefore
higher than the actual BCL2 copy number, and differed from
the GeneCount result in all 38 tumors with translocation (Fig-
ure 5a). After recalculating the FISH copy numbers as
described [22], the consistency in the data was excellent,
except in one case at a corrected FISH value of five copies
(Figure 5b). This discrepancy was due to failure of GLAD and
GeneCount estimations of tumor cell fractionFigure 3
GeneCount estimations of tumor cell fraction. Tumor cell fraction of 
lymphomas estimated by GeneCount is plotted against tumor cell fraction 
measured by flow cytometry. Each point represents mean ± standard 
deviation based on the values achieved for q within the range 0.7-0.9. The 
smoothed aCGH ratios from (a) GLAD and (b) CGH-explorer, the q 
range 0.7-0.8, and a DI determined by flow cytometry were inputs to 
GeneCount. The calculations were based on 55 (a) and 43 (b) tumors for 
which suitable ratio levels for the calculations existed. Correlation 
coefficients and P-values from Pearson product moment correlation 
analyses are indicated.
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CGH-Explorer in detecting a narrow amplicon involving
BCL2 (panel C in Additional data file 4).
GeneCount analysis of solid tumors
The feasibility of our method for analysis of solid tumors
without information of tumor cell fraction was explored in 99
cervical cancers, for which the DI ranged from 1.00-3.16. The
tumor cell fraction could be estimated for 93 and 89 tumors
based on GLAD and CGH-Explorer, respectively, fulfilling the
requirements for this estimation (Materials and methods).
The tumor cell fractions were poorly correlated with the val-
ues determined by analysis of histological sections (Addi-
tional data file 5). In most cases, the histology result was
higher than the GeneCount estimate, probably because
immune cells infiltrating the tumor parenchyma were not
properly quantified by the histological examination. In a few
cases, however, the histology result was higher, probably
reflecting that different parts of the sample were used in the
aCGH and histology analyses. The tumors for which the
tumor cell fraction could be estimated by GeneCount were
included in the further analyses.
A higher number of genetic aberrations were generally found
in the cervical cancers than in the lymphomas. High level
amplifications with more than 2.5-fold increases in gene
dosage (that is, copy number, N, relative to total DNA content
given by two times the DNA index (N/(2.DI)), were found in
about half of the tumors and most frequently on chromo-
somes 5p and 11q. GeneCount analysis showed copy numbers
within the range of 5-80 in these regions, which were often
surrounded by gains at lower levels.
The GeneCount results were compared with the outcomes of
existing analysis methods, where gains and losses were
scored from the smoothed ratio levels and breakpoints
obtained by GLAD and CGH-Explorer. The log2 transformed
ratio levels of ± 0.2 (that is, approximately two times the ratio
standard deviation (Additional data file 6)) were applied as
cut-off levels for scoring aberrations. We selected genes that
were shown to be affected by gains and losses in previous
studies on a subgroup of the patients [27]. Some of the genes
showed only a small variation in the aCGH ratios, often
within the level of ± 0.2, and only a few tumors with aberra-
tions were identified (Figure 6a and panel A in Additional
data file 7). A higher number of patients with changes in gene
copy numbers and in the corresponding gene dosages were
identified with GeneCount, using the cut-off levels of ± 0.2 for
scoring gene dosage changes (Figure 6b,c and panels B and C
in Additional data file 7). The gene dosage correlated signifi-
cantly with gene expression (Figure 6c and panel C in Addi-
tional data file 7), making the copy number changes
determined by GeneCount plausible.
The copy number changes of MRPS23 have previously been
shown to correlate with survival probability [27]. Survival
analysis based on the GeneCount data of MRPS23 identified
more patients with poor outcome than the corresponding
analysis based on ratio levels (Figure 6d,e). Hence, 15 high
risk patients were identified based on the GeneCount results,
whereas only 5 patients were classified with high risk based
on the ratio levels. Nine of the ten patients that were not iden-
tified based on ratio levels (blue curve in Figure 6d) had ane-
uploid tumors with a DNA index ranging from 1.10-1.92. The
remaining diploid tumor had a relatively low tumor cell frac-
tion of 23%.
GeneCount estimations with unknown tumor cell fractionFigure 4
GeneCount estimations with unknown tumor cell fraction. DNA copy 
number calculated by GeneCount, using a q-value within the range 0.7-0.9, 
a DI determined by flow cytomery, and the tumor cell fraction estimated 
by GeneCount in Figure 3, is plotted against the corresponding FISH result 
for 9 genes in (a) 55 and (b) 43 lymphomas. The smoothed array CGH 
ratio derived from GLAD and CGH-explorer was used in (a) and (b), 
respectively. Grey and blue columns represent GeneCount results that 
were consistent and inconsistent with the FISH data, respectively, after 
rounding off the GeneCount value. Frequency distributions are shown for 
each copy number, containing 1, 19, 134, 56, 11, 5, 4, and 1 value at a FISH 
copy number of 0, 1, 2, 3, 4, 5, 6, and 8, respectively, based on GLAD. The 
corresponding numbers based on CGH Explorer were 1, 15, 98, 48, 7, 5, 
4, and 1.
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Intratumor heterogeneity in DNA copy numbers
Some tumors had genome regions for which the aCGH ratio
was clearly different from that corresponding to an integer
copy number. This probably reflected intratumor heterogene-
ity in the DNA copy numbers, that is, the existence of subpop-
ulations with copy number changes that are not common for
all tumor cells in the sample. The common aberrations can
thus be considered homogeneous. Lymphomas and cervical
cancers with heterogeneous DNA regions had ratio levels that
fell in between, and were significantly different from, those
GeneCount estimations in the t(14;18) translocated region involving BCL2Figure 5
GeneCount estimations in the t(14;18) translocated region involving BCL2. BCL2 copy number estimated by GeneCount, using a q-value of 0.8 and a DI and 
tumor cell fraction determined by flow cytometry, is plotted against the corresponding FISH result in 94 lymphomas. The smoothed array CGH ratios 
derived from GLAD and CGH-explorer were used in the left and right panels, respectively. Grey and blue columns represent GeneCount calculations that 
were consistent and inconsistent with the FISH measurements, respectively, after rounding off the GeneCount value. (a) Uncorrected FISH data are 
plotted; (b) these data were corrected as described in [22]. Frequency distributions are shown for each copy number, containing 1, 38, 33, 13, 5, and 1 
value for a red spot FISH copy number of 1, 2, 3, 4, 5, and 6. The corresponding number of measurements for the corrected FISH data of 1, 2, 3, 4, 5, and 
6 were 1, 69, 14, 4, 2 and 1.
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corresponding to integer values (Figure 7). The actual ratio
level reflected the proportion of cells with that aberration
(Equation 1).
Nineteen (20%) lymphomas and 44 (50%) cervical cancers
had one or more heterogeneous DNA regions with copy num-
bers 1&2, 2&3, or 3&4 (Additional data files 8 and 9). Reliable
detection of heterogeneity required tumor cell fractions above
24% (Additional data file 10) and 5 out of 93 cervical cancers
were therefore excluded from this analysis. Lymphoma
L309/89 (Figure 7) had previously been identified as hetero-
geneous by FISH, showing one population with three and
another with four copies of MYC and centromeres 8 and 17
[20]. Moreover, several of the heterogeneous aberrations in
the cervical cancers, such as loss on chromosome 4 and X and
gain on 11q and 17 in C005/01, loss on 6q and gain of 11q in
C006/01, and loss on 4 in C023/01, were similar to those
detected earlier by conventional CGH [14]. The previous
study was, however, based on a different set of biopsies,
which probably explains the lack of consistency for some of
the tumors.
In a few of the heterogeneous tumors, two different ratio lev-
els were identified between one and two copies (Figure 8 and
Additional data file 11). Thus, it appeared that the corre-
sponding aberrations were present in different fractions of
the tumor cell population. Lymphoma L008/92 had two
intermediate ratio levels between one and two copies, corre-
sponding to 70% and 30% of the tumor cells (Figure 8b, blue
and red ratios, respectively), leading to the possible tumor
evolutionary schemes depicted in Figure 8c. As the sum of the
two fractions did not exceed 100%, the heterogeneous aberra-
tions may be found in non-overlapping subpopulations of the
tumor, where the subpopulations have evolved differently
from a predicted common population containing the homog-
enous aberrations (parallel sequence). A serial sequence,
where the populations have evolved in a linear manner from
a common population, was also possible. In C024/01, how-
ever, the heterogeneous ratio levels corresponded to 78% and
44% of the tumor cells, and a serial sequence was the only one
suggested (panel C in Additional data file 11).
Discussion
We have shown that GeneCount is a reliable method for
genome-wide calculation of DNA copy numbers in clinical
tumor samples. Such data are biologically interesting in
themselves but may also lead to improved prediction of
treatment outcome and aid in the identification of novel
tumor suppressors and oncogenes. We applied the method to
lymphomas, for which accurate measures of tumor cell frac-
tion and DNA copy numbers have been obtained by other
techniques that could be compared with the GeneCount
results. We further used the method on cervical cancers, for
which tumor cell fractions representative of the aCGH data
are more difficult to achieve by a separate technique. The
GeneCount analyses in cervical cancersFigure 6
GeneCount analyses in cervical cancers. (a) Frequency histogram (number 
of tumors) of smoothed aCGH ratios (GLAD) for MRPS23 (BAC clone ID 
RP11-19F16). Dotted lines indicate the cut off ratio levels of ± 0.2, 
identifying 5 tumors with genetic gain and 3 tumors with loss. (b) 
Frequency histogram (number of tumors) of MRPS23 copy number 
calculated by GeneCount. The GLAD ratio levels, the DI measured by flow 
cytometry, and the tumor cell fraction estimated by GeneCount were 
used in the calculation. Similar results were achieved based on the CGH-
Explorer ratio levels. (c) Plot of gene expressions against gene dosage; 
that is, the MRPS23 copy number divided by the total DNA content (N/
(2·DI)). Increased gene dosage with more than 15% of the total DNA 
content (log2 transformed gene dosage of at least 0.2) were seen in 15 
tumors (red and blue symbols). Red symbols represent the five tumors 
with gain in (a), whereas blue symbols represent the remaining ten tumors 
with increased gene dosage that were not identified in (a). The correlation 
coefficient and P-value from Pearson product moment correlation analysis 
are indicated. (d) Kaplan Meier analysis based on GeneCount results for 
MRPS23. Plots of the survival probability are shown for 5 patients with 
high gene dosage in (c), who also had gain in (a) (red line), 10 patients with 
high gene dosage in (c) and without gain in (a) (blue line), and 78 patients 
with low gene dosage in (c). (e) Kaplan Meier analysis based on the 
MRPS23 ratio levels. The survival probability of 5 patients with gain in (a) 
(red line) and 88 patients without gain in (a) (black line) is plotted. Only 
five high risk patients were identified in (e), whereas ten more patients 
were identified by GeneCount in (d). P-value in log-rank test is indicated in 
(d,e). Panels (a,b,d) are based on 93 tumors, for which the tumor cell 
fraction could be estimated by GeneCount. Panel (c) is based on 89 of 
these tumors, for which both DNA copy number and gene expression 
were available.
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GeneCount model is simple, due to the use of normal cells
with two DNA copies throughout the genome as a reference
sample. Moreover, the estimated copy numbers are restricted
to positive integers, increasing the robustness of the method.
A requirement for achieving the absolute quantification for-
mat is the use of pre-determined tumor ploidies, whereas the
tumor cell fractions, if not known, and experimental bias can
be estimated from the aCGH data.
The experimental bias is mainly caused by signals from
unsuppressed repetitive sequences and nonspecific hybridi-
zation [2]. The bias influences the test and reference sample
equally and independently of the DNA copy number, since it
is generated by sequences distributed throughout the
genome. The bias could, therefore, be summed up in an array
specific factor, q, representing the dynamics of the log-trans-
formed ratios. Mohapatra et al. [19] included the bias as a
constant factor affecting the absolute, rather than the log-
transformed, ratios in their model for pure tumor cells. Our
approach seems justified because the noise (width) of the log-
transformed ratios was independent of the ratios and, there-
fore, of the DNA copy numbers (Additional data file 6). We
allowed for a small variation in q when calculating the tumor
cell fraction to account for minor differences in the bias
across the tumors. This q-value, optimized for each tumor,
was highly similar to the mean q determined from control
experiments, indicating that the bias was stable across exper-
iments. Moreover, the discrepancies between the GeneCount
and FISH results were related to the specific genetic aberra-
tion involved and, therefore, to the breakpoint detection
algorithm, rather than to possible uncertainties in q. Recent
developments in array CGH technology, utilizing oligonucle-
otides rather than bacterial artificial chromosome (BAC)
clones, led to improved ratio dynamics and reduction in the
experimental bias due to less repetitive sequences [28].
Ongoing work in our laboratory shows that by using oligoar-
rays, GeneCount can be applied with a q value close to 1.
Inclusion of the tumor cell fraction is a prerequisite for the
calculation of absolute DNA copy numbers in clinical tumor
samples. The lymphoma data were based on single cell sus-
pensions made from the entire lymph nodes. A tumor cell
fraction representative of the lymph node could, therefore, be
determined with high accuracy by a separate technique like
flow cytometry. In solid tumors such as cervical cancers, the
normal cells consist of stroma, which is highly heterogene-
ously distributed within the tissue, and immune cells, which
infiltrate the tumor parenchyma. A measure of the tumor cell
fraction achieved by, for example, histological examination,
which is based on a part of the sample different from that
used for the aCGH experiment and/or fails to quantify the
proportion of immune cells accurately, is, therefore, not pre-
cise enough for the calculation of DNA copy numbers.
Histology data may, however, be useful for preselecting
tumor enriched samples for the aCGH analysis. Fairly stable
estimates of the tumor cell fraction, consistent with the values
GeneCount identification of DNA copy number heterogeneity within tumorsFigure 7
GeneCount identification of DNA copy number heterogeneity within 
tumors. (a) Frequency histogram (% array probes) of aCGH ratios in a 
heterogeneous lymphoma, including data for the entire genome. (b) 
aCGH ratios are plotted against chromosomal location, showing the 
heterogeneous regions on chromosomes 8, 9, and 17 with a DNA copy 
number of 3&4 in blue. (c) Frequency histogram (% array probes) of 
aCGH ratios for two homogeneous DNA regions with a copy number of 
3&4 (upper panel) and the heterogeneous region depicted in (b) with a 
copy number of 3&4 (lower panel). The ratio distributions of copy number 
3, 4, and 3&4 were significantly different (p < 0.001, ANOVA). DNA copy 
numbers estimated by GeneCount from the DI and tumor cell fractions 
measured by flow cytometry are marked; those in black were consistent 
with FISH experiments, whereas those in red have not been subjected to 
FISH measurements in the specific tumors shown. The arrows in (b) point 
to the locations of the FISH probes. Note that the 3&4 copy number of 
the heterogeneous region has been confirmed with FISH.
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measured by flow cytometry, were achieved by the use of
GeneCount. The estimates led to DNA copy numbers in agree-
ment with the FISH data, suggesting that the accuracy of the
tumor cell fractions was sufficient for reliable data analysis.
Selection of appropriate ratio levels for the estimation was
crucial for achieving this accuracy. We required that the
tumors had at least two aberrations with different copy num-
bers and with more than ten array probes each to reduce
errors caused by poorly defined ratio levels and breakpoints.
Moreover, only ratio levels deviating more than 0.15 (log2
scale) from the baseline were selected, implying that tumor
fractions higher than 24% (diploid) and 36% (tetraploid)
were needed when copy numbers were changed to 3 or 5 cop-
ies, respectively (Additional data file 12).
The few discrepancies between the GeneCount and FISH data
were not related to our model, but rather to the ability of the
statistical methods to detect some of the aberrations. Hence,
the consistency between the GeneCount and FISH results was
similar to the reliability of GLAD in detecting breakpoints in
simulated data [9]. The highest accuracy of the GeneCount
results was obtained for well defined aberrant regions con-
taining at least three array probes. In these cases a ratio level
representative of the corresponding copy number was
achieved and the probability of detecting the aberration was
high. The increased uncertainty in the results of narrow aber-
rations implies that they should be confirmed by a separate
technique like FISH. Moreover, to ensure sufficient ratio
dynamics and, therefore, a high probability of breakpoint
detection, a tumor cell fraction higher than a certain value,
which depends on the experimental noise and tumor ploidy,
is needed. With the noise of our experiments (Additional data
file 6), a tumor cell fraction above 23% in diploid, and some-
what higher in hyperdiploid cases, enabled separation of an
aberration with more than three array probes (Additional
data file 13). This fraction also enabled detection of heteroge-
neous DNA copy numbers involving more than ten array
probes (Additional data file 10). In experiments with more
Figure 8
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Evolutionary sequences of subpopulations in heterogeneous tumorsFigure 8
Evolutionary sequences of subpopulations in heterogeneous tumors. (a) 
Frequency histogram (% array probes) of aCGH ratios in a heterogeneous 
lymphoma is shown, including data for the entire genome. (b) The aCGH 
ratios are plotted against chromosomal location. The heterogeneous 
regions on chromosomes 2q, 5p, 7q, 9p, 13q, 20q, and Xp with a DNA 
copy number of 1&2 and on chromosomes 2p, 4q, 6p, 11q, and 18 with a 
DNA copy number of 2&3 are shown in blue and red. The blue and red 
colors represent aberrations that are present in different fractions of the 
tumor cells; 70% and 30%, respectively. The heterogeneous aberrations 
are listed in Additional data file 8 except those with a copy number of 2&3, 
since the lack of 3 DNA copies in this tumor prevented statistical analysis 
to identify 2&3 heterogeneity. (c) Schematic diagram of two possible 
evolutionary sequences for the aberrations, one parallel and one serial 
sequence, are shown. The blue and red circles represent the blue and red 
aberrations in (b). The percentages indicate the fractions of tumor cells 
with the listed aberrations, as calculated by GeneCount, showing that the 
aberrations in blue and red are present in 70% and 30% of the tumor cells, 
respectively.
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noise, caused by, for example, poor DNA quality, higher
tumor cell fractions are required. In comparison, at least 50%
tumor cells is suggested for optimal detection of gains and
losses by conventional CGH [29].
The DNA copy number of genes involved in translocations
cannot be directly assessed by FISH when a probe covering
the breakage region is used, because signals from both the
original chromosomes are detected in the translocated
derivatives. Correction of the probe signal to achieve the true
copy number requires knowledge of the breakpoint and genes
involved in the translocation. Reliable FISH analysis in solid
tumors, where the translocations are not well identified and
may occur throughout the genome [30] is, therefore, particu-
larly challenging. By aCGH, the probe signal is measured
independently of the actual genome organization of the DNA
covered by the probe. Hence, in the case of balanced translo-
cations, a correct result will be obtained even if the probe cov-
ers the breakpoint. If the probe is located at the start or end of
an amplified or deleted region (unbalanced translocation),
the aCGH ratios of the adjacent probes ensure that the correct
copy number is calculated. Our model therefore provides a
novel method for assessment of copy numbers both in bal-
anced and unbalanced translocated regions and without
knowing that the translocation exists.
Current methods for analysis of aCGH data generally score
genetic gains and losses based on ratio levels [31-36]. The
breakpoints in individual tumors can be detected with high
accuracy by use of statistical algorithms like GLAD and CGH-
Explorer. However, the existing downstream analyses, using
common ratio levels for scoring aberrations across tumors,
fail to identify gains and losses in cases of high ploidy and
normal cell content. By the use of GeneCount, the ratio levels
are replaced with the absolute copy numbers relative to the
total DNA content as measures of gene dosage, which can be
compared across tumors regardless of ploidy and normal cell
content. Hence, copy number changes that were not detected
by analysis based on ratio levels, but showed significant cor-
relation with gene expression, were found in cervical cancers,
suggesting that improved results were achieved. Moreover,
many patients with poor outcome that had MRPS23 gain by
GeneCount had no gain based on ratio levels. In the latter
case, the gain was masked by high content of normal cells or
high ploidy, showing that GeneCount is more sensitive in
detecting patients with genetic aberrations. The finding fur-
ther demonstrates that GeneCount applies well to solid
tumors for which the tumor cell fraction is generally unknown
and must be estimated by the method. Advances in current
statistical analysis methods may utilize adjustable ratio levels
for scoring gains and losses, optimizing the cut-off ratios for
each tumor based on a mathematical evaluation of the ratio
dynamics. Such methods may account for varying ploidy and
normal cell content across diploid, triploid, and tetraploid
tumors. However, the strategy is not useful for tumors with an
intermediate ploidy like 1.25 (Figure 1c). In contrast, the
absolute DNA copy number relative to the total DNA content,
or gene dosage, is comparable also across such tumors.
We also showed that GeneCount can provide genome-wide
and high resolution information of intratumor heterogeneity
in the DNA copy numbers. Such heterogeneity has previously
been detected only on a single gene basis by FISH or at low
resolution by conventional CGH analyses [14,15,20,37,38],
probably reflecting a high genomic instability [39]. Detection
of heterogeneity involving two DNA copies by the use of FISH
is challenging, since the heterogeneous tumor population is
difficult to distinguish from normal cells. The probability to
detect heterogeneity with GeneCount depends on the fraction
of tumor cells with the heterogeneous aberration. Obviously,
the probability is largest at a fraction of 50%, but fractions
higher than 70% and lower than 30% were also identified.
Heterogeneity in low copy numbers, like 1&2 and 2&3, are
more easily detected, since the separation between the log-
transformed ratio levels are larger. At higher copy numbers,
the possibility to detect heterogeneity decreases, depending
on the ploidy and normal tissue content. However, we also
identified heterogeneous regions with copy number 3&4 in
several tumors and 4&5 in one tumor. Finally, the probability
to detect heterogeneity also depends on the proportion of the
genome that is affected. In our data severe heterogeneity
affecting up to 40% of the genome could be analyzed with
GeneCount (C002/01; Additional data file 9). With an
increasingly larger part of the genome affected, difficulties in
finding breakpoints and even homogeneous aberrations
eventually occur, leading to unreliable results regardless of
analysis method.
The heterogeneity data led to insight into the evolutionary
sequence of the copy number changes. The homogeneous
aberrations had probably occurred prior to the heterogeneous
ones [14]. Moreover, in cases where the heterogeneous aber-
rations appeared to be present in different fractions of the
tumor cell population, these aberrations could be ordered
chronologically in a serial and/or parallel sequence. It was
not always possible to identify the correct sequence among
the proposed ones, as could be done by comparing data for
several biopsies from the same tumor [14]. However, identifi-
cation of the heterogeneous as well as the homogeneous aber-
rations suggests a further possible investigation of the exact
combination of aberrations in each subpopulation, employ-
ing, for example, triple-color FISH with one probe for a
homogeneous aberrant region and two for the heterogeneous
ones.
In the heterogeneity analysis we assumed that the ploidy was
the same for all subpopulations of malignant cells. This
assumption was justified because no cases were observed
with two aneuploid populations by flow cytometry. A possible
difference in the ploidy of two aneuploid populations within a
tumor was therefore probably smaller than 10%, leading to
less than 10% uncertainty in the copy numbers calculated by
Genome Biology 2008, 9:R86
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GeneCount (Equation 4; data not shown). The same uncer-
tainty also applied to near diploid and heterogeneous cervical
cancers. These tumors often showed a broad G1 peak with a
CV up to 10% by flow cytometry, probably reflecting the exist-
ence of several subpopulations with ploidy within the range of
1.0-1.1. Moreover, few or no light chain positive cells were
observed in the diploid population of the aneuploid lympho-
mas, suggesting that the diploid population contained prima-
rily normal cells. It is possible, however, that the diploid
population of the aneuploid cervical cancers contained
malignant cells, as we have previously shown for aneuploid
colorectal cancers [40]. This might have led to larger uncer-
tainties in the heterogeneous copy numbers due to the use of
an erroneous DNA index of the diploid population. The data
of such tumors can be improved by sorting the diploid and
aneuploid fractions by flow cytometry [40] for separate aCGH
and GeneCount analyses.
Conclusion
GeneCount provides reliable DNA copy numbers, both when
based on the tumor cell fractions determined by flow cytome-
try and those estimated by the method. Accurate data are also
achieved in translocated chromosomal regions, as demon-
strated for the t(14;18) translocation involving BCL2. Our
method is the only one to provide genome-wide information
of absolute DNA copy numbers. Moreover, the method repre-
sents a significant improvement compared to existing meth-
ods in the study of gene dosages and intratumor copy number
heterogeneities. The robustness of GeneCount implies that
the method can be utilized widely in the genomic exploration
of both hematopoietic and solid tumors, addressing DNA
copy number aspects in a reliable manner, regardless of pos-
sible translocations. This may lead to improved assays for dis-
ease classification and outcome prediction and aid the
identification of efficient targets for new cancer therapies.
Materials and methods
Tumor samples, DNA index, and tumor cell fraction
Samples from 94 patients with B-cell non-Hodgkin's lym-
phoma and 99 patients with squamous cell carcinoma of the
uterine cervix were analyzed. We used fresh frozen lym-
phoma cell suspensions for which the tumor subtype, stage,
patient treatment, and follow-up have been presented previ-
ously [25]. The cervical cancers were of FIGO (Fédération
Internationale des Gynaecologistes et Obstetristes) stage 1b-
4b, treated with radiotherapy. Tumor biopsies taken before
the start of treatment were used.
The DI of the lymphomas and cervical cancers and the tumor
cell fraction of the lymphomas were determined by use of flow
cytometry, and most of these data have been published earlier
[14,23,25]. The lymphoma cells were labeled with phyco-
erythrin-labeled antibodies to the tumor characteristic light
chains for identifying the tumor cells and Hoechst 33258 for
assessment of DNA content. The DI was determined from the
G1 peak position of the light chain positive cells relative to the
light chain negative cells. Tumor cell fraction was determined
as the fraction of light chain positive cells. The DI of the cer-
vical cancers was assessed by preparing clean nuclei, stained
with propidium iodide, using the detergent-trypsin method
[41]. Cells from a diploid cell line were used as an internal ref-
erence. Samples showing two distinct G1 peaks in the DNA
histogram were classified as aneuploid, and the DI was deter-
mined from the position of the G1 peak of the aneuploid cells
relative to the corresponding peak of the diploid cells. Sam-
ples with a single G1 peak were classified as near diploid. An
estimate of the tumor cell fraction was achieved for each cer-
vical cancer sample by histological examination of hematoxy-
lin and eosin stained sections derived from the middle part of
the biopsies. These values were used to compare with the
tumor cell fractions estimated by GeneCount.
Array CGH
Genomic array slides produced by the Microarray Facility at
the Norwegian Radium Hospital were used [42]. The arrays
contained 4,549 unique genomic clones of BACs and P1 arti-
ficial chromosomes (PACs) (Wellcome Trust Sanger Institute,
Cambridge, UK) that covered the whole genome with a reso-
lution of approximately 1 Mb. The 1 Mb clone collection was
supplemented with tiling path probes between 1q12 and 1q25,
using overlapping BACs and PACs. The clones were from the
RPCI-11 (BAC) and the RPC1-1, -3, -4, and -5 (PAC) libraries.
Each clone was printed in 4-8 array spots. The genes covered
by the clones were found from Ensembl [43].
Genomic DNA was isolated from the lymphoma cell suspen-
sions and cervical cancer biopsies according to a standard
protocol, including proteinase K, phenol, chloroform, and
isoamylalcohol [44]. DNA (1 g) was digested overnight,
using DpnII endonuclease (New England Biolabs, Beverly,
MA, USA), and purified using the QIAquick PCR Purification
Kit (Qiagen, Valencia, CA, USA). Digested and purified DNA
and normal reference DNA (0.5 g each) were labeled by a
random primer reaction (BioPrime DNA Labeling System,
Invitrogen, Carlsbad, CA, USA) with Cy3-dCTP and Cy5-
dCTP (Perkin-Elmer Life Sciences, Foster City, CA, USA),
respectively, and co-hybridized to the array slides [42]. Scan-
ning and image analysis were performed by use of an Agilent
scanner (Agilent Technologies Inc., Palo Alto, CA, USA) and
the GenePix 6.0 image analysis software (Axon Instruments
Inc., Union City, CA, USA). The microarray management and
preprocessing software BASE [26] was used for spot filtering
and ratio normalization. The mean value of the 4-8 spots of
each genomic clone was used, provided that the standard
deviation was less than 0.2. Lowess normalization was per-
formed so that the mean log-transformed ratio of all clones
was equal to 0. The GLAD and CGH-Explorer algorithms
were used for ratio smoothing and breakpoint detection
[9,11]. Default values of 8 (GLAD) and 1.5 (CGH-Explorer) for
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the statistical penalty, , were used. The smoothed ratios were
inputs to GeneCount.
Principle of GeneCount
For a heterogeneous test sample consisting of several cell
populations, like normal cells and distinct populations of
malignant cells, the DNA of each cell population contributes
to the aCGH ratio. Ideally (that is, in cases of no experimental
bias), the normalized ratio of each array probe is given by:
where Rideal is the aCGH ratio of a sample with n cell popula-
tions, and Ni, DIi, and Fi are the DNA copy number, DNA
index, and tissue fraction of cell population i, respectively. We
assume that: the reference sample is normal DNA with a copy
number of 2 throughout the genome, except for the X and Y
chromosomes in males; sex-matched hybridizations are per-
formed; and DI is given relative to the DNA content of normal
cells.
In cases of a homogeneous sample with a single cell popula-
tion, for example, a cancer cell line, Equation 1 is reduced to:
In clinical samples with two cell populations, that is, malig-
nant and normal cells, the ratio is given by:
where NT, DIT, and FT are the DNA copy number, DNA index,
and fraction of malignant cells in the sample, respectively. 1 -
FT represents the fraction of normal cells, which have a DI of
1 and DNA copy number (N) of 2.
It was clear from experiments where normal male DNA was
hybridized against female DNA that the ratio dynamics were
somewhat reduced (Figure 1e). A dynamic factor, q, was
included in Equation 3 to compensate for this effect. Since the
experimental noise was independent of the logarithm of the
ratio (Additional data file 6), Equation 3 was rewritten to
account for the reduced dynamic in the following way:
The dynamic factor represents the systematic, non-random
reduction in the log-transformed ratios caused by the experi-
mental bias and has a value between 0 and 1, where the latter
value occurs in the ideal situation without any reduction in
the ratio dynamics. The factor is a characteristic of the array
slide series and the laboratory protocol and was determined
from the ratio of the X chromosome in a control experiment
hybridizing male versus female normal DNA (Figure 1e).
Equation 4 was used in GeneCount to calculate FT and NT
from the ratio profile of the sample.
Intratumor heterogeneity in the DNA copy numbers, that is,
the cases of several populations of malignant cells in addition
to the normal cells, was identified by selecting the tumors for
which one or more of the aCGH ratio levels were different
from that corresponding to an integer value by visual inspec-
tion. The ratio distributions of the potential heterogeneous
regions were compared to the distributions of the adjacent
homogeneous aberrations by ANOVA analysis, and a P-value
of 0.05 was required to classify the aberration as heterogene-
ous. The fraction of tumor cells with a heterogeneous aberra-
tion was calculated, employing the more general Equation 1.
The DI was assumed to be the same for all subpopulations of
malignant cells.
Implementation of GeneCount in BASE
We used BASE as a platform for GeneCount and linked the
algorithm to the output of the GLAD and CGH-Explorer pack-
ages, which were implemented in our BASE version. The
method can also be developed as a separate program or inte-
grated in other aCGH analysis packages. The algorithm con-
sists of three major steps: data input for all samples;
estimation of tumor cell fraction in the cases when this
parameter is unknown; and estimation of DNA copy number
for each array probe (panel A in Additional data file 1). The
smoothed aCGH ratios served as input, together with the DI,
the q-value from control experiments with its lower and
upper limits (qmin, qmax) and, if available, the tumor cell
fraction.
In cases of unknown tumor cell fraction, this value was esti-
mated in a simulation procedure based on two selected ratio
levels, using the tumor cell fraction and DNA copy numbers
as independent and q as dependent variables. The copy num-
bers and tumor cell fraction were increased in steps of 1 and
0.01, respectively, and the corresponding q-value was calcu-
lated (panel B in Additional data file 1). To ensure high accu-
racy in the estimated fractions, it was required that the
absolute value of the selected ratio levels was larger than 0.15.
This implied that samples with a tumor cell fraction lower
than 24% in diploid and 36% in tetraploid tumors could not
be analyzed when only aberrations involving one copy
number change existed (Additional data file 12). Moreover, a
minimum absolute difference of 0.2 - that is, approximately
two times the standard deviation of the log-transformed ratio
levels (Additional data file 6) - between the two selected ratio
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levels was needed. To further increase the reliability of the
estimation, only ratio levels with more than ten probes were
selected. We optimized q for each tumor by allowing the value
to vary within the limited range of qmin to qmax, typically q ±
10%, leading to fairly stable estimates of the tumor cell frac-
tion. The mean tumor cell fraction based on these estimates
and the corresponding mean q-value was used in Equation 4
to estimate the DNA copy numbers of the tumor. In cases of
known tumor cell fraction, this fraction and q from control
experiments were used in Equation 4. The source code of the
module is provided by communication to the authors. A demo
version of GeneCount in BASE is also available [45].
Fluorescence in situ hybridization
GeneCount estimates for the lymphomas were compared with
direct assessments of gene copy numbers by use of FISH. All
FISH analyses have been published previously [20-25]. Dual-
color FISH was applied to all 94 tumors. We used spectrum
orange labeled locus-specific propidium iodide DNA probes
for genes commonly aberrant in lymphomas (CCND3, BMP6,
PIM1, MYC, CDKN2A, RB1, TP53, PMAIP1, and MALT1) and
spectrum green labeled centromer probes (centromere 1, 6, 8,
17, and 18) (Vysis Inc., Downers Grove, IL, USA) for assessing
the quality of the experiment. For exploring DNA copy
number calculations in translocated chromosomal regions,
BCL2, which is frequently involved in the translocation
t(14;18)(q32;q21) in lymphomas, was considered. A dual-
color translocation probe involving BCL2 and covering the
breakpoint region was used (LSI IGH Spectrum Green/LSI
BCL2 Spectrum Orange, Vysis Inc.). Due to splitting of the
probe signal in cases of translocation, erroneous high BCL2
copy numbers were derived directly with this probe. The
BCL2 copy number was therefore corrected based on the sig-
nals from the IGH and centromere 18 probes, as described
[22].
Gene expression microarrays
Gene expressions were determined by microarray analysis of
89 of the cervical cancers and related to the GeneCount esti-
mates. We used array slides produced at the Microarray Facil-
ity at the Norwegian Radium Hospital, containing 15,000
cDNA clones. The data from 48 of the patients, with a detailed
description of the experimental procedures, have been pre-
sented [27]. Cy3- and Cy5-labeled cDNA was synthesized
from total RNA by anchored oligo(dT)-primed reverse tran-
scription and co-hybridized with a reference sample (Univer-
sal Human Reference RNA, Stratagene, La Jolla, CA, USA) to
the array slides overnight at 65°C. Scanning and image anal-
ysis were performed with an Agilent scanner and the GenePix
4.1 image analysis software, respectively. Data preprocessing,
including correction of saturated intensities, filtering of weak
and bad spots, and lowess normalization, was performed in
BASE. All hybridizations were performed twice in a dye-swap
design, and the average expression ratio based on the two
experiments was used in the further analyses.
ArrayExpress accession
The array CGH raw data have been deposited to the ArrayEx-
press repository (E-TABM-398, E-TABM-399).
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Additional data files
The following additional data are available with the online
version of this paper. Additional data file 1 is a figure showing
the calculation steps in GeneCount. Additional data file 2 is a
figure showing an example of FISH probe locations. Addi-
tional data file 3 is a figure comparing FISH DNA copy num-
bers and smoothed aCGH ratio levels in non-Hodgkin's
lymphomas. Additional data file 4 is a figure illustrating dis-
crepancies between GeneCount and FISH DNA copy num-
bers. Additional data file 5 is a figure comparing tumor cell
fractions derived by histological examination and by Gene-
Count estimation in cervical cancers. Additional data file 6 is
a figure showing the standard deviation (noise) of the log-
transformed aCGH ratios. Additional data file 7 is a figure
comparing results from ratio level and GeneCount analyses in
cervical cancers. Additional data file 8 is a table listing regions
with DNA copy number heterogeneity in non-Hodgkin's lym-
phomas. Additional data file 9 is a table listing regions with
DNA copy number heterogeneity in cervical cancers. Addi-
tional data file 10 is a figure showing tumor cell fraction
required for detection of heterogeneous copy number
changes. Additional data file 11 is a figure illustrating analysis
of the evolutionary sequence of subpopulations in heteroge-
neous tumors. Additional data file 12 is a figure showing the
minimum tumor cell fraction that can be calculated in Gene-
Count. Additional data file 13 is a figure showing the tumor
cell fraction required for detection of homogeneous copy
number changes.
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STEP 1
Data Input                                                
 Array CGH ratio (R)
 DNA index (DIT)
 Dynamic factor (q, qmin, qmax)
 Tumor cell fraction, FT (optional)
For each tumor
 Is tumor cell fraction known?
STEP 2
 Estimate tumor cell fraction, FT
as described in (B)
STEP 3
For each array probe
 Estimate DNA copy number, NT
from Equation 4
YES
NO
STEP 1
Select two ratio levels (R1, R2)
 Abs (log2 R1, R2) > 0.15
AND
 Abs (log2 R1 - log2 R2 > 0.2) 
AND
 Number of array probes in each level > 10 
STEP 2
For N1 = 1 to 6 and N2 = 1 to 20, in steps of 1.0 
For FT = 0 to 1, in steps of 0.01     
 Calculate q from Equation 4
B
STEP 3
For q within range (qmin, qmax)
 FT = FT mean
Calculation steps in GeneCount.
Float diagrams of the entire GeneCount procedure (A) and the estimation of tumor cell fraction 
(B) are shown. Data input in (A) includes the aCGH ratio levels, R, derived from statistical 
analysis tools, the DNA index (DIT) of the tumor cells, the dynamic factor, q, of the experiment, 
and the tumor cell fraction, FT. FT can either be measured by a separate technique like flow 
cytometry, or estimated by the procedure in (B). In the former case, a fixed q-value, as 
determined from control experiments, is used. Otherwise, q is estimated for each tumor as 
indicated in (B), allowing for a deviation of typically 10% (range qmin - qmax) from the value 
determined in control experiments. To calculate tumor cell fraction, two ratio levels, R1 and R2,
are selected, and the DNA copy numbers N1 and N2, corresponding to R1 and R2, respectively, 
are predicted in a stepwise manner by increasing N1 from 1 to 6 and N2 from 1 to 20 in steps of 
1. R1, R2, and the incremental values of  N1 and N2 are used in a simulation procedure based 
on Equation 4, allowing FT to vary from 0 to 1 in steps of 0.01, and calculating the 
corresponding q. The FT values obtained for q within the range qmin – qmax are used to 
calculate a mean FT representative of the tumor. The mean FT is further used as input to the 
algorithm in (A) to calculate the DNA copy numbers of all array probes. The criteria used to 
select R1 and R2 for estimation of tumor cell fraction are described in the Materials and 
methods section of the paper. The source code of the GeneCount module is available by 
communication to the authors. 
Additional data file 1
0 30 60 900 30 60 90 120 150
-2.0
-1.5
-1.0
-0.5
0.0
0.5
1.0
0 30 60 90
Location on chromosome 6, 13 and 18
aC
G
H
 ra
tio
 (l
og
2)
BMP6
CCND3PIM1
Centromere
PMAIP1 BCL2
Centromere
Chromosome 6 Chromosome 13 Chromosome 18
6
4
3
2
1
5
D
N
A copy num
ber
RB1
L358/87. Tumor cell fraction: 89%; DNA index: 1.94
Example of FISH probe locations.
ACGH ratios are plotted against chromosomal location on chromosomes 6, 13, and 18 
in a tetraploid lymphoma with a tumor cell fraction of 89%. FISH probes for BMP6,
PIM1, CCND3, centromere 6, RB1, PMAIP1, BCL2, and centromere 18 were used in 
this particular tumor, and their location is marked. The copy numbers determined with 
FISH were 3 (RB1), 4 (PMAIP1, BCL2), and 6 (BMP6, PIM1, CCND3).
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FISH DNA copy numbers in relation to smoothed aCGH ratio levels. 
Smoothed aCGH ratio levels derived from GLAD (A) and CGH-Explorer (B) is plotted 
against the corresponding FISH results for 9 genes in 94 lymphomas. Frequency distributions 
are shown for each copy number, containing 1, 25, 246, 66, 15, 5, 4, and 1 values at a FISH 
copy number of 0, 1, 2, 3, 4, 5, 6, and 8, respectively. 
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L458/88
RP11-305D15: RB1
RP11-174I10: RB1
Smoothed ratio by CGH-Explorer
Smoothed ratio by GLAD
Discrepancies between GeneCount and FISH DNA copy numbers.
(A) shows a deletion involving RB1 that was detected by GLAD but not by CGH-Explorer. The 
GeneCount estimate was 1.1 and 1.9 based on GLAD and CGH-Explorer, respectively. The RB1 copy 
number determined by FISH was 1. (B) shows a homozygote deletion involving RB1, where the ratio 
level was inappropriately determined since the deleted region contained only two array probes. The 
GeneCount estimate was 0.5 and 1.9 based on GLAD and CGH-Explorer, respectively. The RB1 copy 
number determined by FISH was zero. (C) shows a gain involving BCL2, which was not detected by 
GLAD or CGH-Explorer. The GeneCount estimate was 2.3 and 2.1 based on GLAD and CGH-Explorer, 
respectively. The BCL2 copy number determined by FISH was 5. There was no t(14;18) translocation in 
this tumor.
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Histological examination and GeneCount estimation of tumor cell fraction.
Plots of tumor cell fraction of cervical cancer samples estimated by GeneCount versus tumor cell 
fraction measured by histological examination of tumor sections. Each point represents mean ±
SD based on the values achieved for q within the range 0.7 – 0.9. The smoothed aCGH ratios 
from GLAD (A) and CGH-explorer (B), the q range 0.7 – 0.8, and a DI determined by flow 
cytometry were inputs to GeneCount. The calculations were based on 93 (A) and 89 (B) tumors, 
for which suitable ratio levels for the calculations existed. Correlation coefficients and P-values 
from Pearson product moment correlation analyses are indicated.
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Standard deviation (SD) versus mean of the log-transformed ratio distributions achieved for 
94 lymphomas (A) and 99 cervical cancers (B) is shown. The individual ratio levels 
determined by the breakpoint detection algorithm in GLAD were considered. The median 
and mean SD is indicated. Note that the SD was independent of the mean ratio and 
therefore of the DNA copy number.
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Ratio level and GeneCount analyses in cervical cancers.
In (A) frequency histogram (number of tumors) of smoothed aCGH ratios (GLAD) is shown 
for ANXA4 (BAC clone ID RP11-304A15) (left panel) and MGC14151 (RP11-144K9) (right 
panel). Stippled lines indicate the cut off ratios of ±0.2, identifying 7 (ANXA4) and  17 
(MGC14151) tumors with genetic gain or loss. In (B) frequency histogram (number of 
tumors) of DNA copy number calculated by GeneCount is shown for ANXA4 (left panel) and 
MGC14151 (right panel). The GLAD ratio levels, the DI measured by flow cytometry, and 
the tumor cell fraction estimated by GeneCount were used in the calculation. Similar results 
were achieved based on the CGH-Explorer ratio levels. In (C) plot of gene expressions 
against  gene dosage; i.e., the ANXA4 (left panel) and MGC14151 (right panel) copy number 
divided by the total DNA content (N/(2·DI)), is shown. The gene dosage was changed; i.e.,
higher than 0.2 or lower than -0.2, in 26 (ANXA4) and 40 (MGC14151) tumors; i.e., in 
considerable more tumors than when only the ratio levels were used. Correlation coefficient 
and P-value from Pearson product moment correlation analysis are indicated. Panels A and B 
are based on 92 (ANXA4) and 91 (MGC14151) tumors, for which GeneCount data existed. 
Panel C is based on 85 of these tumors, for which both DNA copy numbers and expression 
were available.
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Table 1. DNA copy number heterogeneity in non-Hodgkin’s lymphomas 
Patient DNA index DNA regiona DNA copy number 
L122/84 1.23 17q24-ter 1&2
L255/85 1.04 12p 1&2
L358/87 1.94 9pter-q21, 9q31-ter 3&4
L47/88 1.00 11q14-22 1&2
L154/88 0.95 4 1&2
L399/88 1.00 11q13-14, X (male) 1&2
22 2&3
L064/89 1.26 17 2&3
L309/89 1.83 8, 9, 17q21-ter 3&4
L339/89 1.00 17q21-25 2&3
L034/90 1.16 X (male) 1&2
L472/90 1.16 X 2&3
L577/90 1.97 4 2&3
11 3&4
3 4&5
L382/91 1.02 13q32-ter 1&2
L383/91 0.97 11q22-23, 15q25-ter 1&2
L436/91 1.04 Xq26-ter (male) 1&2
L462/91 1.00 3pcen-14, 3p21-22, 3p24-ter, 15qcen-15, 17p11-ter 1&2
L008/92 1.00 2q, 5p13-ter, 7q31-ter, 9p21-23, 13q14-31, 20q13-ter, Xp22-ter  1&2
L037/92 1.00 19 1&2
L117/92 1.00 4 1&2
aThe aCGH ratios of the heterogeneous DNA region were significantly different from those of the 
homogeneous regions in all cases, as verified from ANOVA analysis. 
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Table 2.  DNA copy number heterogeneity in cervical cancers 
Patient DNA index DNA regiona DNA copy number 
C002/01 1.00 1p34-ter, 10, 16, 17, 19, 20 1&2
2pter-q33, 5p14-q14, 6, 7p11-ter, 8, 12pter-q23, X 2&3
C003/01 1.90 5pter-q12, 6, 11pter-q12, 12, 13q21-31, Xp 3&4
C004/01 1.00 17q23-ter, X 2&3
C005/01 1.70 1p33-ter, 4, 7q,  Xpter-q27  2&3
3q, 6q13-ter, 7p, 10pter-q24, 11pter-q22, 17, 18, 20  3&4
C006/01 1.30 6q24-ter 1&2
1p32-ter, 11q12-13, 17q, 18, 19, 22q 2&3
C008/01 1.00 9q 2&3
C014/01 1.94 3p 3&4
C023/01 1.00 2q33-ter, 4, 8p 1&2
1p32-qter, 3, 7q21-ter 2&3
C024/01 1.00 1p31-ter, 2q21-ter, 4p, 8p, 13qcen-34 1&2
6p 2&3
C025/01 1.00 21qcen-21, X 1&2
9 2&3
C028/01 1.00 X 1&2
9 2&3
C041/01 1.34 8 3&4
C045/01 1.00 3p 1&2
C053/01 1.00 1p34-ter 1&2
C054/01 1.00 2q33-ter, 9qcen-22, Xq22-ter 1&2
15 2&3
C078/02 1.70 5q, Xpter-q28 3&4
C092/02 1.00 3p, 8p12-ter, 17, 19, 20, 22 1&2
1p34-ter, 2p13-ter, 8p12-q11, 8q13-ter, 13q, 18 2&3
C093/02 2.00 17pter-q25, 18 3&4
C101/02 1.50 2, 4, 20q11-ter 2&3
1, 3p 3&4
C115/03 1.00 2p21-11, 17q21-ter, 18q21-ter 2&3
C120/03 1.00 22 1&2
8, 18, X 2&3
C130/03 1.60 4, 5qcen-14,  7, 17pter-q21  2&3
12q, Xq 3&4
C136/03 1.40 4p15-ter, 19pter-q13 1&2
6p12-ter, 8q22-ter, X  2&3
C138/03 1.90 7p11-22, 12, 15 3&4
C141/03 1.10 5q23-ter, 20q12-ter 2&3
C142/03 1.00 3q24-ter, X 2&3
C144/03 1.50 3p, 19 2&3
3q, 4q13-ter,  7, Xp22-q21 3&4
C152/03 1.00 3q 2&3
C162/04 2.16 10q, 12q, 18q, 21 3&4
C169/04 1.00 18q12-ter, 21qcen-21 1&2
C174/04 1.95 1p32-ter, 16, 19, 20, 22 3&4
C178/04 1.00 5q, 17p, 21 1&2
1q, 13q22-ter, 16, 20 2&3
C180/04 1.92 11p, 18q11-21, 2&3
3p, 7, 13q32-ter, 18q21-ter 3&4
C184/04 1.39 3p, 14, 17p, Xpter-q25 2&3
1pter-q32, 8q21-ter 3&4
C188/04 1.00 2, 5q, 6pter-q25, 10, 11, 15, 18 1&2
9q22-ter, 12p11-ter, 12q13-ter, 16 2&3
C189/04 1.50 4q, Xp11-ter 1&2
17pter-q24 2&3
C190/04 1.00 3p, 4, 8, 13 1&2
C193/04 1.00 1pcen-31, 3p, 4p15-qter, 5, 6p21-q24, 8, 14qcen -21, 18 1&2
C194/04 1.00 5q, 9p, 11p15-q13, 18p12-ter, 22q13-ter 1&2
16q, 19p, 20 2&3
C195/04 1.90 1p32-q12, 2p11-ter, 12q, 14, 15 3&4
C196/04 1.00 2q12-q33, 4p13-qter, 17p, X 1&2
C202/04 1.00 13q21-q32 1&2
C206/04 1.00 4, 13q21-q31 1&2
1p31-ter, 19, 22 2&3
C215/04 1.00 11p, 13q21-ter 1&2
1p31-ter 2&3
aThe aCGH ratios of the heterogeneous DNA region were significantly different from those of the 
homogeneous regions in all cases, as verified from ANOVA analysis. 
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Tumor cell fraction required for detection of heterogeneous copy number changes.
The tumor fraction needed for statistically significant separation of a heterogeneous chromosomal 
region involving more than ten (solid lines) or three (stippled lines) array probes from a 
homogeneous region without aberration is shown as a function of the DNA index (DI). The curve 
for heterogeneous gain (copy number 2·DI + 0.5) and loss (copy number 2·DI - 0.5) is shown in 
green and red color, respectively. A Student t-test and a standard deviation of 0.1 for the log-
transformed ratio distributions were used to estimate the curves. It was assumed that the 
heterogeneous gain and loss affected 50% of the tumor cells in the sample. Data showing the tumor 
cell fraction of 94 lymphomas (closed symbols) and 93 cervical cancers (open symbols), as 
determined by flow cytometry (lymphomas) and estimated by GeneCount from the GLAD ratio 
levels (cervical cancers) are included.
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Evolutionary sequence of subpopulations in heterogeneous tumors.
In (A) frequency histogram (% array probes) of aCGH ratios in a heterogeneous 
cervical cancer is shown. Data of the entire genome are included. In (B) the aCGH
ratios are plotted against chromosomal location. The heterogeneous regions on 
chromosomes 1p, 2q, 4p, 8p, and 13q with a DNA copy number of 1&2 and on 6p 
with a DNA copy number 2&3 are shown in blue and red. The blue and red colors 
represent aberrations of two different fractions of the tumor cells, 78% and 44%, 
respectively. The heterogeneous aberrations are listed in Additional Data File 9. In (C) 
schematic diagram of the possible evolutionary sequence for the aberrations are shown. 
The blue and red aberrations refer to the blue and red aberrations in (B). The 
percentages indicate the fractions of tumor cells with the listed aberrations, as 
calculated by GeneCount, showing that the aberrations in blue and red are present in 
78% and 44% of the tumor cells, respectively. 
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Minimum tumor cell fraction that can be calculated in GeneCount.
The tumor fraction needed for achieving ratio levels of 0.15 above the baseline, assuming a copy 
number gain (green) or loss (red) of 1 (stippled lines) and 2 (dotted lines) copies, is shown as a 
function of the DNA index (DI). The curves were calculated from Equation 4. Data showing the 
tumor cell fractions of 94 lymphomas (closed symbols) and 93 cervical cancers (open symbols), as 
determined by flow cytometry (lymphomas) and estimated by GeneCount from the GLAD ratio 
levels (cervical cancers) are included. 
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Tumor cell fraction required for detection of homogeneous copy number changes.
The tumor fraction needed for statistically significant separation of an aberrant chromosomal region 
involving more than three (solid lines) or ten (stippled lines) array probes from a region without 
aberration is shown as a function of the DNA index (DI). The curve for gain and loss of one DNA 
copy (copy number 2·DI ± 1) is shown in green and red color, respectively. A Student t-test and a 
standard deviation of 0.1 for the log-transformed ratio distributions were used to estimate the curves. 
Data showing the tumor cell fractions of 94 lymphomas (closed symbols) and 93 cervical cancers 
(open symbols), as determined by flow cytometry (lymphomas) and estimated by GeneCount from 
the GLAD ratio levels (cervical cancers) are included. 
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Abstract
Integrative analysis of gene dosage, expression, and ontology (GO) data was performed to discover driver genes in the
carcinogenesis and chemoradioresistance of cervical cancers. Gene dosage and expression profiles of 102 locally advanced
cervical cancers were generated by microarray techniques. Fifty-two of these patients were also analyzed with the Illumina
expression method to confirm the gene expression results. An independent cohort of 41 patients was used for validation of
gene expressions associated with clinical outcome. Statistical analysis identified 29 recurrent gains and losses and 3 losses
(on 3p, 13q, 21q) associated with poor outcome after chemoradiotherapy. The intratumor heterogeneity, assessed from the
gene dosage profiles, was low for these alterations, showing that they had emerged prior to many other alterations and
probably were early events in carcinogenesis. Integration of the alterations with gene expression and GO data identified
genes that were regulated by the alterations and revealed five biological processes that were significantly overrepresented
among the affected genes: apoptosis, metabolism, macromolecule localization, translation, and transcription. Four genes on
3p (RYBP, GBE1) and 13q (FAM48A, MED4) correlated with outcome at both the gene dosage and expression level and were
satisfactorily validated in the independent cohort. These integrated analyses yielded 57 candidate drivers of 24 genetic
events, including novel loci responsible for chemoradioresistance. Further mapping of the connections among genetic
events, drivers, and biological processes suggested that each individual event stimulates specific processes in
carcinogenesis through the coordinated control of multiple genes. The present results may provide novel therapeutic
opportunities of both early and advanced stage cervical cancers.
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Introduction
Cervical cancer is one of the most common malignancies
affecting women worldwide and a major cause of cancer death for
women globally [1]. Radiotherapy combined with cisplatin is the
treatment of choice at the locally advanced stages [2]. Improved
therapy is needed, since more than 30% of the patients show
progressive disease within 5 years after diagnosis and treatment
related side effects to organs within the pelvis are frequent. Tumor
stage, size, and lymph node involvement are the most powerful
markers of aggressive disease, but do not fully account for the
observed variability in outcome and are not biologically founded.
A better handling of the disease may be provided by the discovery
of efficient biomarkers for therapeutic planning and intervention,
but requires more insight into the mechanisms underlying cervical
carcinogenesis and treatment relapse.
During carcinogenesis, genetic and epigenetic alterations drive
the evolution of tumor towards increased malignancy and
treatment resistance. The changes enable tumor cells to overcome
microenvironmental constraints, sustain proliferation, and invade
adjacent tissues and distinct organs [3–5]. Gene dosage alterations
like gains and losses regulate the expression of genes and are
motive forces for this evolution [6,7]. Tumor cells bearing an
increasing number of gains and losses successively emerge and are
selected for based on the growth advantage caused by the genetic
changes. Discovery and functional assessment of gene dosage
alterations involved in carcinogenesis are therefore essential for
understanding the biology of the disease.
At the locally advanced stages of cervical cancer, numerous
gene dosage alterations and severe aneuploidy are frequently seen
[8–10]. Moreover, pronounced intratumor heterogeneity in the
gains and losses exists within the tumors, reflecting a high genetic
instability [9]. The consequences of these alterations for the tumor
phenotype are difficult to predict, since large chromosomal regions
involving multiple genes are generally affected and some
aberrations may be random events without biological significance
[11]. Genome wide screening of DNA copy numbers in a decent
number of patients enables identification of recurrent gene dosage
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alterations; i.e., alterations characteristic of the disease, and
alterations associated with the clinical outcome [12], which are
likely to be important in carcinogenesis and treatment resistance.
Combining the data with expression profiles of the same tumors
reveals the genes that are regulated primarily by the genetic
events. The potential of this integrative strategy was recently
demonstrated in a study on 15 early stage cervical cancers, where
genes affected by aberrations on 1q, 3q, 11q, and 20q were
reported [13]. Genetic events promoting tumor evolution and
treatment resistance have, however, not been explored on a
genome wide scale, and their biological meaning has not been
addressed.
The present work was conducted to discover candidate driver
genes and assess their function in the carcinogenesis and
chemoradioresistance of cervical cancers. Genome wide screening
of DNA copy numbers and expressions was performed in 102
patients with locally advanced disease. Of these, pairwise data
were available for 95 patients. Reliable comparison of gains and
losses across the patients was ensured by using the tumor ploidy, as
determined by flow cytometry, and the GeneCount method to
correct for the normal cell content of the samples and extract the
absolute copy numbers and thereby the gene dosages [14]. The
use of GeneCount also enabled mapping of the intratumor
heterogeneity in the gene dosage alterations, providing informa-
tion of the chronological order in which they had occurred during
tumor evolution [14]. The recurrent gene dosage alterations, the
alterations associated with outcome after chemoradiotherapy, and
the genes that were regulated by these alterations were identified.
Further analysis of gene ontology (GO) categories [15] was
performed to identify biological processes that were overrepre-
sented among the affected genes and therefore probably regulated
by the gene dosage alterations. Such large scale and combined
genomic, transcriptional, and functional analysis is powerful in
detection of driver genes and their biological meaning, but has not
been presented before. We demonstrate the potential of this
approach by the identification of five biological processes in
carcinogenesis that were associated with recurrent and predictive
gains and losses of a set of genes. The set included four genes
within the predictive losses for which repressed expression was
related to poor outcome in the patient group and in an
independent cohort of 41 patients. The genes are candidate
drivers of the genetic events and novel biomarkers of cervical
cancers.
Results
Recurrent Gene Dosage Alterations
Cervical cancer patients subjected to curative chemoradiother-
apy were included in the study (Table 1). Most cases were
squamous cell carcinoma and human papillomavirus (HPV)
positive. Aneuploidy was seen in about half of the tumors,
including some of the adenosquamous carcinomas and HPV
negative cases (Figure S1A, S1B). Based on 97 patients, we
generated an absolute gene dosage profile of the cancer genome by
the use of array comparative genomic hybridization (aCGH) and
Author Summary
Genetic gains and losses, i.e. changes in gene dosages, are
common abnormalities of human cancers. Discovering
these defects and understanding the biological meaning
can lead to improved therapeutic opportunities. This
paper reports a large scale screening of gene dosage
alterations in cervical cancer and gives a broader
exploration of the expression and function of genes with
gains or losses. We have focused on the most frequent
gene dosage alterations and the alterations associated
with survival after chemoradiotherapy, since these defects
are likely to be of major importance for developing
disease. The most notable finding was the discovery of a
set of biological processes that are known hallmarks of
cancer and were associated with gains and losses of
specific genes. Moreover, novel loci associated with
chemoradioresistance independent of existing clinical
markers were found, and the genes involved were
depicted. Our results indicated that gene dosage alter-
ations play a causative role in the carcinogenesis and
chemoradioresistance of cervical cancer and pinpointed
candidate biomarkers of the disease.
Table 1. Patient and tumor characteristics.
Characteristic
Basic cohort
(n =102)
Validation
cohort (n =41)
Histology (n)
Squamous 96 40
Adenocarcinoma 1 0
Adenosquamous carcinoma 5 1
HPV status (n)a,b
HPV16 65 35
HPV18 7 0
HPV16+18 11 1
HPV other 10 4
HPV negative 8 1
FIGO stage (n)
1B 6 2
2 57 27
3 35 9
4A 4 3
Tumor sizec: vol (cm3)d, diameter (cm)e
Median 45.1, 4.4 36.6, 4.1
Range 2.8–321, 1.8–8.5 8.7–192, 2.5–7.2
Pelvic lymph node statusc (n)
Positive 37 12
Negative 65 29
Age (years)
Median 56 55
Range 28–85 25–81
Observation time (months)
Median 42 31
Range 21–71 24–46
Relapse 32 12
aPCR on DNA was performed, using the primers listed in [9]. The products were
detected by polyacrylamide gel electrophoresis or the Agilent DNA 1000 kit
(Agilent Technologies Inc., Germany).
bHPV status was not determined for one patient in the basic cohort due to lack
of DNA for analysis.
cTumor size and lymph node status were determined from pretreatment
magnetic resonance (MR) images.
dVolume was calculated based on 3 orthogonal diameters (a,b,c) as (p/6)*abc.
eDiameter was calculated from tumor volume (4p/3)*r3.
doi:10.1371/journal.pgen.1000719.t001
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the GeneCount analysis tool (Figure 1A). All chromosomes were
affected with gains and losses, however, some regions were more
frequently found to be aberrant than others (Figure 1B). Clustering
of the patients based on gene dosages revealed no clear groups
with characteristic aberrations.
The recurrent gains and losses were identified by considering
both the amplitude and frequency of each alteration in Figure 1B
[16]. Hence, a larger weight was given to high-amplitude events
that are less likely to be random aberrations without biological
significance. The recurrent alterations comprised more than 42%
of the genome, and consisted of 14 regions (528 Mb) with gain and
15 (734 Mb) with loss (Figure 1C). Most of these alterations were
also seen in the adenosquamous carcinomas and the HPV
negative tumors (Figure S1C, S1D). The most common alterations
were gain on 1q, 3q, 5p, 20q, and Xq and loss on 2q, 3p, 4p, 11q,
and 13q, each involving 44–76% of the patients (Figure 1C,
Table 2). High level amplification (seven regions) and homozygote
deletion (six regions) helped to depict the peak of five recurrent
gains and two recurrent losses (Table 2, Table S1). The frequency
of the homozygote deletions was low (1–3%, Table S1), and none
Figure 1. Gene dosage alterations of locally advanced cervical cancers. (A) Absolute gene dosage profile of 97 patients. Patients are shown
in columns and gene dosages are ordered by DNA location in rows. The color scale ranges from green (loss) through black (neutral) to red (gain). Grey
indicates missing values. (B) Frequency of patients with gains (red) and losses (green) along chromosome 1 to X for the patients in (A). Gene dosage
alterations above 1.1 and below 0.9 were classified as gains and losses, respectively. (C) Score of recurrent gains (red) and losses (green) along
chromosome 1 to X for the patients in (A). Peak regions, defined in Table 2, are shown in darker colors. (D) Intratumor heterogeneity in gene dosage
alterations along chromosome 1 to X for the patients in (A). The heterogeneity index is shown for gains (above the zero line) and losses (below the
zero line) separately, and was calculated as the number of heterogeneous cases relative to the total number of cases with alteration at each DNA
location. The peak regions shown in (C) are marked in red (recurrent gains) and green (recurrent losses). The predictive losses are indicated in light
blue.
doi:10.1371/journal.pgen.1000719.g001
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Table 2. Gene dosage alterations and correlating genes in locally advanced cervical cancer.
Peak regiona Peak regiona Freq.b
Max./min. gene
dosagec Correlating genesd
(Cytoband) (MB) (%) (copy no.)
Recurrent gain
1p36.21-pter 0–14.6 38 2 (4) SLC35E2, UBE4B, AGTRAP
1p32.1-p34.3 37.3–59.9 40 2 (4) C1orf149, YRDC, RLF, EBNA1BP2, TACSTD2
1q21.1-q22 148.0–153.7 61 2.5 (6) SF3B4, ENSA, GOLPH3L, ARNT, LASS2, ANXA9, POGZ, CGN, SNX27, C1orf77, ILF2,
DENN4B, SLC39A1, UBE2Q1, EFNA1, KRTCAP2, MUC1, FDPS
3q26.1-qtere 166.2–199.5 75 4.5 (9) PDCD10, PHC3, ZNF639, FXR1, PARL, DVL3, ABCF3, ALG3, EIF4G1, SFRS10, DGKG,
EIF4A2, RFC4, CCDC50, PPP1R2, PAK2, NCBP2, DLG1, BDH1, FLYTTD1
5p15.2-ptere 1.0–12.1 47 4 (15) CLPTM1L , MED10, FASTKD3, CCT5, DAP
8q24.13-22 125.7–134.1 37 2 (4) None
8q24.3-qter 144.5–146.3 38 2 (4) TSTA3, FAM83H, CYC1
9p24.1-2e 2.7–6.0 22 13.5 (27) KIAA0020, RCL1
9q34.2-qter 135.6–138.2 35 3.5 (7) MRPS2
11q22.1-2e 100.2–102.0 14 36 (72) YAP1, BIRC3, BIRC2
19q13.11-qter 40.3–63.8 36 10 (29) SPINT2, PSMD8, CAPN12, MRPS12, RPS16, AP2S1, KDELR1, NUP62, ATF5, NKG7,
ZNF787
20q11.21-22e 30.0–33.0 45 3.4 (9) POFUT1, KIF3B, MAPRE1, SNTA1, EIF2S2, AHCY
Xp11.22-pterf 0–54.1 38 2.5 (5) SLC25A6, CD99, ARSD, PNPLA4, PRPS2, PIR, CXorf15, PHKA2, PDHA1, RPS6KA3,
PRDX4, EIF2S3, USP9X, DDX3X, NDUFB11, UBA1, EBP, PLP2, JARID1C, SMC1A,
HUWE1
Xq28-qter 148.5–154.9 47 4 (8) NSDHL, BCAP31, IDH3G, IRAK1, TAZ, LAGE3, UBL4A, FAM34, MTCP1
Recurrent loss
2q33.3-qter 206.2–243.0 54 0.26 (1) NDUFS1, SPAG16, MREG, SMARCAL1, AAMP, WNT10A, ZFAND2B, ANKZF1,
STK11IP, FARSB, ACSL3, HRB, SP100, EIF4E2, COPS8, HDAC4, MTERFD2, PPP1R7
3p12.3-p14.2 60.9–81.6 61 0.26 (1) RYBP, GBE1
4p13-p16.1 8.3–42.3 58 0.42 (1) WDR1, UBE2K, PDS5A
5q13.2g 67.4–71.7 38 0 (0) SMN2
5q14.2-q15 82.5–96.9 35 0.5 (1) COX7C, TTC37, GLRX
6q12-q23.2 67.0–132.9 42 0.43 (1) LMBRD1, MYO6, HMGN3, SYNCRIP, MAP3K7, CCNC, C6orf203, FOXO3, AMD1,
HDAC2, NT5DC1, DSE, NUS1, ECHDC1
7q34-qter 139.3–158.8 35 0.43 (1) PDIA4
8p12-pter 0–31.9 32 0.34 (1) XPO7, BIN3, BNIP3L, EPHX2, CCDC25, DCTN6, PPP2CB
10q23.31g 88.2–92.1 38 0 (0) None
11p14.3-pter 0–24.4 40 0.5 (1) COPB1, PSMA1, GTF2H1, TSG101
11p12 37.8–40.2 37 0.5 (1) None
11q22.3-qter 105.1–134.5 63 0.35 (1) PPP2R1B, C11orf57, TIMM8B, REXO2, C11orf60, TRAPPC4, H2AFX, POU2F3,
ARHGEF12, SC5DL, ZNF202, CHEK1, APLP2, ZBTB44, SNX19
13q12.2-q21.32 27.5–67.4 46 0.33 (1) ALG5, FAM48A, COG6, KIAA1704, GTF2F2, MED4, RNASEH2B
17p11.2-pter 0–19.1 38 0.27 (1) SPAG7, MPDU1, LSMD1, CYB5D1, COPS23
21q21.1-3 18.3–28.6 35 0.28 (1) ATP5J
Predictive loss
3p11.2-p14.1 67.0–87.6 58 0.26 (1) RYBP, GBE1
13q13.1-q21.1 30.0–56.5 46 0.41 (1) ALG5, FAM48A, COG6, KIAA1704, GTF2F2, MED4, RNASEH2B
21q22.2-3 38.0–46.4 23 0.28 (1) PCP4, RIPK4, PDXK
aPeak region of the recurrent gains and losses is the minimum shared region surrounded by at least three patients. In cases of recurrent high level amplification or
homozygote deletion, this event determines the peak region. Peak region of the predictive losses is the region selected by LASSO.
bFrequency is the median percentage of tumors with the alteration.
cGene dosage is absolute DNA copy number divided by ploidy. Maximum (gain) or minimum (loss) gene dosage and corresponding copy number are listed.
dGenes within the peak region showing a correlation between gene dosage and expression are ordered by DNA location.
eRecurrent high level amplification detected within recurrent gain. Peak region is the region with more than 25% higher amplitude than surrounding region.
fProbably two different peak regions.
gHomozygote deletion within recurrent loss. Peak region is the region with a gene dosage of zero.
doi:10.1371/journal.pgen.1000719.t002
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of the tumors had more than one of them. Homozygote alteration
is therefore probably not a common mechanism of gene regulation
in cervical cancers, in contrast to the highly frequent heterozygote
deletion. The highest gene dosage of 36 was found in a diploid
tumor with a copy number of 72 on 11q22.1-2 (Table 2).
Intratumor heterogeneity of the recurrent alterations.
Intratumor heterogeneity in one or more of the gene dosage
alterations was seen in about half of the patients [14]. The ploidy
and genetic alterations of the heterogeneous tumors were similar
to that of the homogeneous ones (Figure S2). It is reasonable to
assume that homogeneous alterations have emerged before the
heterogeneous ones during tumor evolution [9]. To order the
recurrent alterations chronologically in relation to the less
common alterations, we therefore mapped the intratumor
heterogeneity along the chromosomes based on the absolute
data achieved with GeneCount [14]. The heterogeneity was low
for the recurrent alterations compared to others, like gain on 2q
and 13q and loss on 1q, 19q, and 20q (Figure 1D). The recurrent
aberrations had therefore probably occurred prior to many of
these less common events.
Gene Dosage Alterations in Relation to Outcome after
Chemoradiotherapy
Gene dosage alterations responsible for poor clinical outcome
may not be as common as the recurrent ones. All alterations in
Figure 1B were therefore included in the survival analysis. The
LASSO method identified three regions with loss, 3p11.2-p14.1,
13q13.1-q21.1, and 21q22.2-3, which jointly showed the strongest
association to progression free survival (Table 2). The 3p11.2-
p14.1 and 13q13.1-q21.1 regions overlapped with the recurrent
3p12.3-p14.2 and 13q12.2-q21.32 losses, whereas the predictive
loss of 21q22.2-3 was distal of the recurrent loss of 21q21.1-3. The
predictive losses were not correlated and were related to poor
outcome also when analyzed separately (Figure 2A–2C). The
intratumor heterogeneity of the losses was low and similar to that
of the recurrent losses (Figure 1D).
Most patients had more than one of the predictive 3p, 13q, and
21q losses. We therefore investigated whether there was an
increased risk of relapse in cases of two or three losses. Kaplan-
Meier plots for patients with different combinations of the predictive
losses revealed three major groups with different outcome (Figure
S3). Patients without any of the losses had a low risk of relapse and a
survival probability of 91% (Figure 2D). Patients with 3p and/or
13q loss, without 21q loss, had an intermediate survival probability
of 68%, whereas those with 21q loss had the lowest survival
probability of 44%. The risk of relapse therefore seemed to be
particularly high when loss of 21q22.2-3 was involved.
The predictive impact of the 3p, 13q, and 21q losses were
assessed by multivariate analysis together with tumor size, stage,
and lymph node status. Histological type, HPV status, and
heterogeneity status showed no correlation to outcome in
univariate analysis and were therefore not included. The losses
and tumor size had independent predictive value (Table 3),
showing that the gene data contained information of the
progression free survival that was not covered by tumor size.
Since tumor size is a strong predictor (Figure 3A), we also
investigated the predictive impact of the three losses for small and
large tumors separately. About 20% of the patients with tumor size
less than the median had relapse and all of them had one or more
of the losses (Figure 3B). In the cases of tumors larger than the
median, about 47% of the patients progressed and all except two
of them had one or more of the losses (Figure 3C). None of the
patients with loss involving 21q were disease free after 28 months,
suggesting a particularly high risk of relapse in cases of a large
Figure 2. Gene dosage alterations and outcome after chemor-
adiotherapy. Kaplan-Meier curves of progression free survival for
cervical cancer patients with (green) and without (black) loss of 3p11.2-
p14.1 (A), 13q13.1-q21.1 (B), 21q22.2-3 (C), and for patients with
different combinations of the three losses (D). P-values in log-rank test
and number of patients are indicated. Data of the most significant
genomic clone within each region were used; i.e, BAC clone ID RP11-
118O11 (3p), RP11-408L13 (13q), and RP1-128M19 (21q). Total number
of patients in (A, B) is less than 97 due to missing gene dosage data. (A–
C) The lost DNA region is indicated on the chromosome (left). (D) Group
1: patients without loss of 3p11.2-p14.1, 13q13.1-q21.1, or 21q22.2-3,
group 2: patients with loss of 3p11.2-p14.1 and/or 13q13.1-q21.1, but
not 21q22.2-3, group 3: patients with loss of 21q22.2-3 only or loss of
21q22.2-3 combined with loss of 3p11.2-p14.1 and/or 13q13.1-q21.1.
The groups were determined from data of each possible combination
of the losses (Figure S3).
doi:10.1371/journal.pgen.1000719.g002
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tumor bearing loss of 21q22.2-3. There was no difference in tumor
size for patients with and without loss in Figure 3B or in Figure 3C
(data not shown). The gene data therefore enabled identification of
high and low risk patients both in cases of a small and a large
tumor.
Integration of Gene Expression
To find genes regulated by the recurrent and predictive gene
dosage alterations, we used cDNA microarrays and generated a
cancer gene expression profile. The profile was based on 100
patients, including 95 of those analyzed with aCGH. Expression
data were available for 1357 of the about 4000 known genes
within the altered regions, and a significant correlation to gene
dosage was found for 191 of them (Table 2). Several correlating
genes were identified for each region, except for 8q24.13-22,
10q23.31, and 11p12, where no genes were found. Typical
examples of correlation plots are shown in Figure S4. The results
were confirmed with the Illumina gene expression assay on 52
patients. Although the Illumina analysis was based on a lower
number of patients, an excellent correlation between the Illumina
and cDNA data and between the Illumina and gene dosage data
was found for almost all of the genes, as demonstrated in Table S2.
We also performed a second cDNA analysis, including only
tumors with more than 70% tumor cells in hematoxylin and eosin
(HE) stained sections. Totally 179 of the genes (94%) were
identified, suggesting few false positive results due to normal cells
in the samples. The observations supported our conclusion that
the genes in Table 2 were gene dosage regulated. The latter
analysis identified 26 genes that were not depicted when all
patients were considered. These genes were not considered
further, since the results were based on only half of the data set.
Expression of known oncogenes and tumor suppressor genes
within the depicted regions, likeMYC (8q24.21), BRCA2 (13q13.1),
RB1 (13q14.2), and TP53 (17p13.1), was not significantly
correlated to gene dosage. These genes are therefore probably
not regulated primarily by gains and losses. The TP53 and RB1
results were consistent with the high frequency of HPV positive
tumors (Table 1).
The predictive losses on 3p and 13q involved the same
correlating genes as the corresponding recurrent ones, whereas
PCP4, RIPK4, and PDXK were correlating genes within the
Figure 3. Gene dosage alterations and outcome after chemor-
adiotherapy for patients with different tumor size. (A) Kaplan-
Meier curves of progression free survival for cervical cancer patients
with tumor size above (green) and below (black) median. Ninety-two
patients with tumor size determined from diagnostic MR images were
included. Median size was 45.1 cm3, corresponding to a diameter of
4.4 cm. (B,C) Kaplan-Meier curves for patients in (A) with tumor size
below median (B) and above median (C). Group 1: patients without loss
of 3p11.2-p14.1, 13q13.1-q21.1, or 21q22.2-3, group 2: patients with loss
of 3p11.2-p14.1 and/or 13q13.1-q21.1, but not 21q22.2-3, group 3:
patients with loss of 21q22.2-3 only or loss of 21q22.2-3 combined with
loss of 3p11.2-p14.1 and/or 13q13.1-q21.1. The groups were deter-
mined from data of each possible combination of the losses (Figure S3).
P-values in log-rank test and number of patients are indicated.
doi:10.1371/journal.pgen.1000719.g003
Table 3. Cox regression analysis of genetic losses and clinical
variables.
Univariate analysisa Multivariate analysisa
Covariate P HR 95% CI P HR 95% CI
Loss of 3p11.2-p14.1b 0.003 0.27 0.11–0.66 0.018 0.33 0.13–0.83
Loss of 13q13.1-q21.1b 0.006 0.32 0.14–0.72 0.015 0.35 0.14–0.82
Loss of 21q22.2-3b 0.004 0.34 0.16–0.71 0.019 0.32 0.12–0.84
Tumor sizec 0.001 4.5 1.9–10.5 0.001 5.5 1.9–15.5
FIGO staged 0.004 2.9 1.4–5.9 0.072 - -
Total lymph node statuse 0.030 0.46 0.22–0.93 0.285 - -
aP-value (P), hazard ratio (HR), and 95% confidence interval (CI) are listed.
bSemi-discrete gene dosage data of the most significant genomic clone within
each region were used.
cTumor size was divided in two groups based on the median size of 45.1 cm3,
corresponding to a median diameter of about 4.4 cm.
dFIGO stage was divided in two groups; 1b–2b and 3a–4a.
eTotal includes pelvic and para aortal lymph nodes.
doi:10.1371/journal.pgen.1000719.t003
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predictive 21q region (Table 2). To depict the correlating genes
that most probably were involved in development of chemor-
adioresistance, we required that the gene was significantly
associated with clinical outcome both at the gene dosage and
expression level. Moreover, a clear difference in the survival curves
should also be seen in an independent cohort of 41 patients when
based on the Illumina gene expression data. The criteria were
fulfilled for four genes; RYBP and GBE1 on 3p and MED4 and
FAM48A on 13q, which were termed predictive genes (Figure 4).
Two more genes, GTF2F2 and RNASEH2B on 13q, were
correlated to outcome based on the cDNA data, but were not
considered further since the tendency based on the Illumina data
was weak (p.0.15). The relationship to outcome was not strong
enough for PCP4, RIPK4, and PDXK on 21q to be included among
the predictive genes either.
Gene Ontology Analysis
Biological processes associated with the recurrent and predictive
gene dosage alterations were found by comparing the GO
categories of the affected genes with those of all genes in the data
set [15]. One or more biological processes were annotated to 155
of the correlating and predictive genes and to 5824 of all genes.
The categories apoptosis, carbohydrate metabolism, translation,
and RNA-protein complex biogenesis and assembly were
significantly overrepresented among the correlating genes within
the recurrent gains, whereas macromolecule localization, gener-
ation of precursor metabolites and energy, transcription from
RNA polymerase II promoter, and establishment or maintenance
of chromatin architecture were overrepresented among those
within the recurrent and predictive losses (Table 4). Fifty-six genes
were included in the significant categories and were candidate
drivers of the biological processes. In addition, we included the
predictive gene FAM48A, which was not associated to any process
in the GO database, as a potential driver of chemoradioresistance
together with RYBP and MED4 (transcription) and GBE1
(generation of precursor metabolites and energy).
We generated a map to visualize the connections between
genetic events, affected genes, and biological processes (Figure 5).
The processes carbohydrate metabolism and generation of
precursor metabolites and energy were combined in metabolism,
translation and RNA-protein complex biogenesis and assembly
were combined in translation, and transcription from RNA
polymerase II promoter was combined with establishment or
maintenance of chromatin architecture in transcription. The
combined categories were closely related, justifying this strategy.
All but six of the recurrent alterations were associated with a
process and represented in the map. The predictive 3p and 13q
losses were merged with the corresponding recurrent losses, since
the regions overlapped, and linked to metabolism (GBE1) and
transcription (RYBP, MED4) in addition to chemoradioresistance.
The predictive 21q loss was not connected to any known gene, but
associated with chemoradioresistance. The map revealed features
that seemed to be characteristic of recurrent and predictive
alterations in cervical cancer. First, many of the genetic events
were associated with clusters of genes in the same biological
Figure 4. Gene expressions and outcome after chemoradiotherapy. Kaplan-Meier curves of progression free survival for cervical cancer
patients with low (green) and high (black) expression of RYBP (A,E), GBE1 (B,F),MED4 (C,G), and FAM48A (D,H). cDNA data of 100 patients is used in (A–
D), and Illumina data of an independent cohort of 41 patients is used in (E–H) for validation. P-value in log-rank test and number of patients are
indicated. The number of patients in each group was chosen to achieve the largest difference in survival between the groups, approximately
reflecting the number of patients with and without loss in (A–D). Total number of patients is less than 100 in (B) due to missing gene expression data.
doi:10.1371/journal.pgen.1000719.g004
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process. For example, gain on 3q affected three genes in apoptosis
and three in translation, gain on 5p was linked to tree apoptosis
genes, and loss on 6q was associated with four genes in
transcription. Second, several events, like gain on 3q, 19q, 20q
and loss on 2q, 6, and 11q, were connected to more than one
biological process, either through the regulation of several genes or
because some genes had multiple functions.
Discussion
This work presents the first coupling of gene dosage and
expression profiles in a large sample set of cervical cancers. We
based our study on absolute gene dosages, which are more
sensitive than the commonly used aCGH ratios in detecting gains
and losses and enable comparisons across tumors with differences
in ploidy and normal cell content [14]. This strategy and the large
number of patients ensured reliable identification of recurrent
gene dosage alterations, events associated with clinical outcome,
and their intratumor heterogeneity. Further analysis based on GO
categories provided an objective way of organizing the numerous
correlating genes into biological meaningful information. We
demonstrate a large potential of the integrative approach by the
discovery and functional assessment of candidate driver genes that
represent novel biomarkers of the disease. In particular, novel loci
associated with clinical outcome were identified, providing the first
evidence that gene dosage can be responsible for developing
chemoradioresistance in cervical cancers.
The recurrent gene dosage alterations were consistent with
earlier reports on advanced stage cervical cancer based on
conventional CGH [8,9,17]. However, a more precise definition
of the altered regions was achieved here due to the improved
resolution of the array technique. The high frequency of the
alterations suggests that they play a causative role in carcinogen-
esis. Hence, many of the alterations are common also in other
squamous cell carcinomas, like head and neck cancers [18,19].
Moreover, the recurrent loss on 3p and 13q overlapped with the
losses associated with poor clinical outcome, strengthening the
hypothesis of a central role in tumor evolution. Less frequent
alterations can, however, also be crucial for tumor evolution, as
was demonstrated by the recurrent gain on 11q22 in 14 patients
and predictive loss on 21q in 23 patients.
The low intratumor heterogeneity of the recurrent and
predictive gene dosage alterations indicated that they had
occurred prior to many of the other alterations. The result was
consistent with our previous cervical cancer study based on
conventional CGH [9], showing a homogeneous intratumor
distribution of the frequent gains on 3q, 5p, and 20q and losses
on 3p and 11q14-qter. Moreover, regions overlapping with the 1p,
1q, 3q, 8q, 9q, and 20q recurrent gains and 2q, 3p, 4p, 11q, and
17p losses have been found to be altered in precancerous cervical
intraepithelial lesions [17,20–23], suggesting that the events had
occurred at an early stage. It is therefore likely that the alterations
identified here, and the consequently control of biological
processes and development of chemoradioresistance, emerge early
during carcinogenesis. It should be noted that a low heterogeneity
was seen for some of the less common alterations as well, implying
that they had occurred early. The affected genes in these regions
may also be crucial for tumor evolution, however, other
mechanisms than gene dosage alterations, such as epigenetic
events or mutations, probably play the major role in their
regulation. Moreover, some of the highly heterogeneous alter-
ations may be important for disease progression a later stage, being
a result of the continuing tumor evolution towards increased
aggressiveness.
The gene dosage alterations were associated with specific
biological processes that are closely related to known cancer
Table 4. Biological processes overrepresented among the correlating genes within recurrent and predictive regions.
GO number GO category
No. correlating
genes
No. genes
on the array p-value Correlating genes
Gains
GO: 000815 Biological process 93a 5824a
GO: 0006915 Apoptosis 13 (14.0%) 434 (7.5%) 0.026 UBE4B, BIRC2, BIRC3 , ATF5, BCAP31,
CLPTM1L, DAP, FASTKD3, FXR1, NUP62,
PAK2, PDCD10, SLC25A6
GO: 0005975 Carbohydrate metabolism 7 (7.5%) 198 (3.4%) 0.038 PPP1R2, ARNT, PHKA2, POFUT1, PDHA1,
TSTA3, IDH3G
GO: 0006412 Translation 7 (7.5%) 163 (2.8%) 0.015 EIF4G1, EIF4A2, EIF2S2, MRPS12, RPS16,
EIF2S3, MRPS2
GO: 0022613 RNA-protein complex biogenesis and assembly 7 (7.5%) 89 (1.5%) 0.001 EIF4G1, EIF4A2, EIF2S2, EIF2S3,
EBNA1BP2, NCBP2, RCL1
Losses
GO: 000815 Biological process 62a 5824a
GO: 0033036 Macromolecule localization 10 (16.1%) 427 (7.3%) 0.022 BIN3, COPB1, COG6, XPO7, HRB, MYO6,
PDIA4, SNX19, TIMM8B, TSG101
GO: 0006091 Generation of precursor metabolites and energy 4 (6.5%) 117 (2.0%) 0.035 ATP5J, COX7C, GBE1, NDUFS1
GO: 0006366 Transcription from RNA polymerase II promoter 10 (16.1%) 357 (6.1) 0.004 RYBP, FOXO3, GTF2F2, GTF2H1, MED4,
MYO6, POU2F3, SMARCAL1, ZNF202,
HDAC4
GO: 0006325 Establishment or maintenance of chromatin
architecture
5 (8.1%) 140 (2.4%) 0.016 DSE, H2AFX, HDAC2, SMARCAL1,
HDAC4
aGenes with GO annotation (biological process).
doi:10.1371/journal.pgen.1000719.t004
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hallmarks [3–5], indicating that the genes involved are drivers of
carcinogenesis. Hence, gain of the genes in apoptosis, including
the anti-apoptosis genes BIRC2, BIRC3, and ATF5, can help
carcinoma cells to evade apoptosis [3]. Aberrations of the genes in
metabolism, like gain of ARNT and IDH3G in carbohydrate
metabolism, and loss of COX7C and ATP5J in oxidative
phosphorylation, can be part of a metabolic reprogramming
towards increased glycolysis and decreased mitochondrial function
to meet the high energy demand linked to tumor growth [4]. In
particular, gain of ARNT may increase hypoxia and hypoglycemia
tolerance by signaling through the HIF1A pathway [24]. Loss of
the genes in molecular localization, including HRB and TSG101,
can lead to abnormal protein internalization and recycling and
thereby abrogated degradation of proteins like growth factor
receptors [25,26]. Finally, aberrations of the genes in translation
and transcription, such as gain of the translation initiation factors
EIF4A2, EIF4G1, EIF2S2, and EIF2S3 and loss of the transcrip-
tional repressors HDAC2 and HDAC4, can be a way to control the
formation and activity of essential proteins. The EIF-proteins are
central in adaptation to hypoxia and can stimulate MYC
translation and thereby oncogenic processes like cell proliferation
[27,28]. Improper function of HDAC2 and HDAC4 may also
increase proliferation [29]. Many of the genes, including BIRC2,
BIRC3, ATF5, NUP62, FASTKD3, IDH3G, and POFUTI, have
been found to be regulated by gains or losses in previous cervical
cancer studies [30–33]. Our findings link each gene to one or more
specific biological processes, and thereby indicate the functional
meaning of the genetic events in carcinogenesis.
Loss and down regulation of GBE1 and RYBP on 3p and MED4
and FAM48A on 13q were associated with poor clinical outcome,
suggesting that the genes are drivers of chemoradioresistance. The
mechanisms underlying these findings and possible associations to
known aggressive phenotypes like hypoxia and rapid proliferation
[34–36] are not clear, but a tumor suppressor function of the genes
has been indicated. GBE1, which plays a role in carbohydrate
metabolism, has been found to be down regulated in ovarian
cancers [37]. Loss of the transcriptional repressor RYBPmay impair
death receptor-mediated apoptosis [38,39], and the encoded
protein has been shown to be down regulated in many tumor
types, including cervical cancer [40]. Loss of the transcriptional
activatorsMED4may impair transcription of genes with anti-cancer
effect, like the vitamin D receptor [41,42]. The function of FAM48A
is less clear, but some studies indicate that loss of this gene can
promote aggressiveness. Hence, FAM48A is required for activation
of the MAPK p38 pathway [43], which represses cell proliferation
[44]. We found no candidate driver gene of chemoradioresistance
within the predictive loss on 21q. Only a few tumor suppressor
genes have been identified in this region. One candidate is the
transcriptional regulator PRDM15, which was not included in our
cDNA data set [45]. Our data showed, however, no correlation
between PRDM15 expression, assessed with the Illumina method in
52 patients, and gene dosage (data not shown), suggesting that the
gene is not regulated by genetic loss. Further investigation with
denser microarrays or possibly microRNA screening would be
needed to find the drivers in this region.
The connection between genetic events, genes, and biological
processes may provide insight into more general aspects of cervical
carcinogenesis. Several genes were often associated with a single
genetic event, supporting the hypothesis that there can be multiple
drivers of an event that coordinately promote tumor evolution
[11]. In cases of genes in the same biological process, like the anti-
apoptosis genes BIRC2 and BIRC3 on 11q22, a broad and
therefore efficient control of the process may be obtained. Hence,
BIRC2 and BIRC3 may play complementary roles in apoptosis
Figure 5. Genetic events, correlating genes, and biological
processes in carcinogenesis and chemoradioresistance of
cervical cancers. Recurrent and predictive gene dosage alterations,
correlating genes, and biological processes overrepresented among the
genes are listed. Only the genetic events associated with a process or
chemoradioresistance (*) are included; six of the recurrent alterations
are therefore not shown. The genes are ordered by DNA location.
Correlating genes connected to chemoradioresistance were associated
with clinical outcome both at the gene dosage and expression level and
validated in an independent patient cohort. Gains and losses are
indicated with red and green color, respectively.
doi:10.1371/journal.pgen.1000719.g005
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evasion, since upregulation of BIRC3, but probably not BIRC2,
may impair hypoxia induced apoptosis [46,47]. In cases of genes
in different biological processes, such as metabolism (NDUFS1),
macromolecule transport (HRB), and transcription (SMARCAL1,
HDAC4) on 2q, the collective control of these processes through a
single event is likely to give a growth advantage that is selected for
in carcinogenesis. One or more genes in all biological processes
were affected in most tumors due to the high frequency of the
recurrent gene dosage alterations. All processes were therefore
probably important, and the control of them through gains and
losses seems to be a common feature of the disease.
The candidate driver genes represent novel biomarkers that
may be utilized in the handling of cervical cancers. Diagnostic
assessment of the biomarkers may help to understand the
evolutionary status and therefore the biology of the cancer in
individual patients. In particular, the predictive biomarkers may
be used in addition to tumor size for classification of patients into
risk groups in a personalized treatment regime. The biomarkers
also open for the possibility to specifically repress biological
processes in carcinogenesis by molecular targeting, and thereby
interfere with tumor evolution. The use of drugs to inhibit
translation by interaction with EIF-proteins has shown promising
results [48] and been suggested as a tool to target tumor hypoxia
[49]. The approach may be applied at all stages of the disease,
since the genetic events probably emerge early. Moreover,
improved outcome after chemoradiotherapy might be achieved
by targeting the predictive biomarkers. Hence, viral-mediated
delivery of RYBP has been shown to induce apoptosis in a number
of cancer cell lines [38], and could be a useful strategy for the
patients with loss of this gene.
Materials and Methods
Patients
A cohort of 102 patients was included for basic analyses to
identify gene dosage alterations with aCGH (97 patients), affected
transcripts with cDNA microarrays (100 patients), and to confirm
the affected transcripts with the Illumina method (52 patients)
(Table 1). An independent cohort of 41 patients was used to validate
relationships between gene expression and outcome with the
Illumina method (Table 1). All patients received external irradiation
and brachytherapy combined with adjuvant cisplatin and were
followed up as described previously [50]. Eighteen patients received
extended radiation field due to enlarged common iliac and para-
aortal lymph nodes. Progression free survival, defined as the time
between diagnosis and the first event of locoregional and/or distant
relapse, was used as end point. Six patients died of causes not related
to cancer and were therefore censored. Tumor samples were
collected at the time of diagnosis. One – four biopsies, approxi-
mately 56565 mm in size, were taken at different locations of the
tumor, immediately snap-frozen in liquid nitrogen and stored at
280uC until used for analyses. The study was approved by the
regional committee of medical research ethics in southern Norway,
and written informed-consent was achieved from all patients.
Array Comparative Genomic Hybridization
The aCGH experiments and generation of absolute gene dosage
profiles have been described previously for all 97 patients
(ArrayExpress accession no. E-TABM-398) [14]. The array slides
were produced at the Microarray Facility at the Norwegian
Radium Hospital and contained 4549 unique genomic BAC and
PAC clones that covered the whole genome with a resolution of
approximately 1 Mb. Genomic DNA was isolated from the
biopsies, labeled, and co-hybridized with normal female DNA to
the array slides. DNA from different biopsies of the same tumor
was pooled. The biopsies of all except two patients had more than
50% tumor cells in HE stained sections from the middle part of the
sample. Median tumor cell fraction was 70% (range 30–90%).
After array scanning, image analysis, spot filtering, and ratio
normalization, the GLAD algorithm was applied for ratio
smoothing and breakpoint detection [51].
Absolute gene dosages. The smoothed ratios were
transferred to absolute DNA copy numbers in GeneCount by
utilizing tumor ploidy data and correcting for the normal cell
content of the samples [14]. The tumor ploidy was determined
from a separate piece of the biopsy by flow cytometry, and tumor
cell fraction was estimated by the program prior to the copy
number calculations. The ploidy data and tumor cell fractions
have been presented previously [14]. The tumor cell fractions,
ranging from 27% to 84%, were in general lower than the results
based on HE stained sections, probably because the amount of
immune cells infiltrating the tumor parenchyma are difficult to
quantify by histological examination [14]. The copy numbers were
rounded off to the nearest integer values.
The absolute gene dosage profile of each tumor was generated by
dividing each copy number by the ploidy. A gene dosage of 1
therefore implied no change in the copy number. The gene dosage
thresholds for scoring gains and losses were 1.1 and 0.9, respectively,
taking into account an uncertainty in the ploidy measurement of
approximately 10%. For scoring high level amplification, a gene
dosage of 2.5 or higher; i.e. 5 DNA copies in diploid tumors, was
required. Homozygote deletions had a gene dosage of 0.
Intratumor heterogeneity. The intratumor heterogeneity in
the copy numbers was assessed by comparing the aCGH ratio
distributions of the possible heterogeneous regions with the
distributions of the adjacent homogeneous regions by ANOVA
analysis [14]. Totally 86 patients had a tumor cell fraction
sufficiently high for reliable detection of heterogeneity, and the
remaining eleven patients were excluded from this analysis. The
heterogeneous regions have been listed previously [14]. A
heterogeneity index was calculated for gains and losses
separately, as the number of heterogeneous cases relative to the
total number of cases with alteration at each DNA location. The
copy number of the heterogeneous region was 0.5 above (gain) or
below (loss) the nearest integer value.
The GeneCount method has been extensively validated based on
the cervical cancer samples included in this study and a cohort of 94
lymphoma samples [14]. In particular, we used lymphoma samples
to show that the estimated tumor cell fractions correlate significantly
with the highly accurate values determined by flow cytometry [14].
cDNA Microarrays
The cDNA microarray experiments have been presented
previously for 48 of the 100 patients [50]. The array slides were
produced at the Microarray Facility at the Norwegian Radium
Hospital and contained more than 12000 unique cDNA clones,
including most known oncogenes and tumor suppressor genes.
Total RNA was isolated from the biopsies, labeled, and co-
hybridized with reference RNA (Universal Human Reference
RNA, Stratagene, La Jolla, CA) to the array slides. RNA from
different biopsies of the same tumor was pooled. Only biopsies
with more than 50% tumor cells in HE stained sections were
utilized. Median tumor cell fraction was 70% (range 50–90%). All
hybridizations were performed twice in a dye-swap design
(ArrayExpress accession no. E-TABM-817). After array scanning,
image analysis, spot filtering, and ratio normalization, the average
expression ratios were calculated from the two data sets and used
in the further analyses. The gene expressions were mapped to the
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gene dosages based on the exact chromosomal position of the
cDNA and genomic clones, as derived from Ensembl (http://
www.ensembl.org/Homo_sapiens/searchview).
Illumina Gene Expression Beadarrays
Results based on cDNA data were validated with Illumina gene
expression beadarrays in 52 of the patients subjected to aCGH
and in the independent cohort of 41 patients. HumanWG-6 v3
beadchips (Illumina Inc., San Diego, CA) with 48000 transcripts
were used. RNA was isolated from the biopsies as described above
and amplified using the Illumina TotalPrep RNA amplification kit
(Ambion Inc., Austin, TX) with 500 ng of total RNA as input
material. cRNA was synthesized overnight (14 hr), labelled, and
hybridized to the chips at 58uC overnight, according to the
standard protocol. The hybridized chip was stained with
streptavidin-Cy3 (AmershamTM, PA43001, Buckinghampshire,
UK) and scanned with an Illumina beadarray reader. The scanned
images were imported into BeadStudio 3.1.3.0 (Illumina Inc.) for
extraction, quality control, and quintile normalization. The
annotation file HumanWG-6_V3_0_R0_11282955_A was used.
Statistics
The recurrent gene dosage alterations were identified based on
a score that was calculated for each genomic clone by multiplying
the average gene dosage amplitude with its frequency [16]. Gains
and losses were considered in two separate procedures. Semi-
discrete data were used, for which amplitudes lower than 1.1 were
set to 1 when searching for gains and amplitudes higher than 0.9
were set to 1 when searching for losses. The score significance was
assessed by comparison to similar scores obtained after data
permutation [16], adjusting the p-value by a multiple testing
procedure to control the false discovery rate (FDR) [52].
Recurrent alterations with an FDR q-value ,5% were reported.
Gene dosage alterations associated with clinical outcome were
identified with the LASSO method in the Cox proportional
hazards model [53], as implemented in [54]. The LASSO is a
method for variable selection and shrinkage in regression models
when the number of covariates is larger than the number of
individuals. By performing shrinkage in addition to selection, the
LASSO is more stable than stepwise procedures where variables
are either retained or discarded from the model sequentially, one
at a time. In groups of highly correlated variables the LASSO
tends to select only one variable in the group [55], and reported
therefore one representative of each DNA region that jointly
explained the outcome. Each region was thereafter found by
selecting neighbouring genomic clones with strong correlation
(r.0.9) to the one reported. Survival curves were generated by
Kaplan-Meier analysis and compared by using log-rank test.
Spearman’s rank correlation analysis with an FDR q-value ,5%
was used to search for significant correlations between gene dosage
and expression. The analysis was based on semi-discrete data,
retrieved as described above. To identify biological processes that were
overrepresented among the correlating genes, the GO categories of
the genes were compared with those of all genes on the array by using
the master-target procedure with the Fisher’s exact test in the eGOn
software [15]. The GO categories were found in eGOn from public
databases, based on the gene reporter EntrezGeneID.
Supporting Information
Figure S1 Tumor ploidy and gene dosage alterations in relation
to histological type and HPV status. (A) Ploidy distribution of 97
patients. Tumors with a ploidy within the range of 1.8–2.2 were
considered as near diploid. (B) Ploidy of patients with adenosqua-
mous carcinoma or HPV negative tumor. (C, D) Frequency of
patients with gains (red) and losses (green) along chromosome 1 to
X for patients with adenosquamous carcinoma (C) and HPV
negative tumor (D). Gene dosage alterations above 1.1 and below
0.9 were classified as gains and losses, respectively. (A–D) Tumors
in the basic cohort subjected to aCGH analysis were included.
Found at: doi:10.1371/journal.pgen.1000719.s001 (0.30 MB TIF)
Figure S2 Tumor ploidy and gene dosage alterations in
homogeneous and heterogeneous tumors. (A) Ploidy distribution
of patients with homogeneous (left) and heterogeneous (right)
tumors. (B,C) Frequency of patients with gains (red) and losses
(green) along chromosome 1 to X for patients with homogeneous
(B) and heterogeneous (C) tumor. Gene dosage alterations above
1.1 and below 0.9 were classified as gains and losses, respectively.
Totally 86 patients with a tumor cell fraction sufficiently high for
reliable detection of heterogeneity were included in the analysis.
Found at: doi:10.1371/journal.pgen.1000719.s002 (0.29 MB TIF)
Figure S3 Clinical outcome for patients with different combi-
nations of predictive losses. Kaplan-Meier curves showing
progression free survival after chemoradiotherapy of 97 cervical
cancer patients with different combinations of 3p11.2-p14.1,
13q13.1-q21.1, and 21q22.2-3 loss. The different combinations
and number of patients in each group are listed (right). P-value in
log-rank test is indicated.
Found at: doi:10.1371/journal.pgen.1000719.s003 (0.24 MB TIF)
Figure S4 Correlations between gene dosage and expression.
Typical correlation plots of gene dosage and expression for 9
correlating genes within the recurrent and predictive regions; 6 with
gain and 3 with loss. Spearman’s rank correlation analysis on semi-
discrete data was performed, for which amplitudes lower than 1.1
were set to 1 for gains and amplitudes higher than 0.9 were set to 1
for losses. Correlation coefficient (R) and p-value are indicated.
Found at: doi:10.1371/journal.pgen.1000719.s004 (0.27 MB TIF)
Table S1 Recurrent high-level amplifications and homozygous
deletions in locally advanced cervical cancer.
Found at: doi:10.1371/journal.pgen.1000719.s005 (0.03 MB PDF)
Table S2 Relationships among Illumina, cDNA, and gene
dosage data for correlating genes.
Found at: doi:10.1371/journal.pgen.1000719.s006 (0.07 MB PDF)
Acknowledgments
We wish to thank Thea Smedsrud at the Microarray Facility, the
Norwegian Radium Hospital, for help with the Illumina experiments.
Author Contributions
Conceived and designed the experiments: ML HL. Performed the
experiments: ML DHS. Analyzed the data: ML MH LCB TS KS IKG
GBK HL. Contributed reagents/materials/analysis tools: MH LCB KS
IKG GBK. Wrote the paper: ML MH LCB DHS TS KS IKG GBK HL.
References
1. Cannistra SA, Niloff JM (1996) Cancer of the uterine cervix. N Engl J Med 334:
1030–1038.
2. Eifel PJ (2006) Concurrent chemotherapy and radiation therapy as the standard
of care for cervical cancer. Nat Clin Pract Oncol 3: 248–255.
3. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57–70.
4. Kroemer G, Pouyssegur J (2008) Tumor cell metabolism: cancer’s Achilles’ heel.
Cancer Cell 13: 472–482.
5. Mosesson Y, Mills GB, Yarden Y (2008) Derailed endocytosis: an emerging
feature of cancer. Nat Rev Cancer 8: 835–850.
6. Albertson DG (2006) Gene amplification in cancer. Trends Genet 22: 447–455.
Driver Genes in Cervical Cancer
PLoS Genetics | www.plosgenetics.org 11 November 2009 | Volume 5 | Issue 11 | e1000719
7. Knuutila S, Aalto Y, Autio K, Bjorkqvist AM, El-Rifai W, et al. (1999) DNA
copy number losses in human neoplasms. Am J Pathol 155: 683–694.
8. Heselmeyer K, Macville M, Schrock E, Blegen H, Hellstrom AC, et al. (1997)
Advanced-stage cervical carcinomas are defined by a recurrent pattern of
chromosomal aberrations revealing high genetic instability and a consistent gain
of chromosome arm 3q. Genes Chromosomes Cancer 19: 233–240.
9. Lyng H, Beigi M, Svendsrud DH, Brustugun OT, Stokke T, et al. (2004)
Intratumor chromosomal heterogeneity in advanced carcinomas of the uterine
cervix. Int J Cancer 111: 358–366.
10. Rao PH, Arias-Pulido H, Lu XY, Harris CP, Vargas H, et al. (2004)
Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the
frequent genetic changes in cervical carcinoma. BMC Cancer 4: 5.
11. Albertson DG, Collins C, McCormick F, Gray JW (2003) Chromosome
aberrations in solid tumors. Nat Genet 34: 369–376.
12. Davies JJ, Wilson IM, Lam WL (2005) Array CGH technologies and their
applications to cancer genomes. Chromosome Res 13: 237–248.
13. Wilting SM, de WJ, Meijer CJ, Berkhof J, Yi Y, et al. (2008) Integrated genomic
and transcriptional profiling identifies chromosomal loci with altered gene
expression in cervical cancer. Genes Chromosomes Cancer 47: 890–905.
14. Lyng H, Lando M, Brovig RS, Svendsrud DH, Johansen M, et al. (2008)
GeneCount: genome-wide calculation of absolute tumor DNA copy numbers
from array comparative genomic hybridization data. Genome Biol 9: R86.
15. Beisvag V, Junge FK, Bergum H, Jolsum L, Lydersen S, et al. (2006) GeneTools
- application for functional annotation and statistical hypothesis testing. BMC
Bioinformatics 7: 470.
16. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, et al. (2007)
Assessing the significance of chromosomal aberrations in cancer: methodology
and application to glioma. Proc Natl Acad Sci U S A 104: 20007–20012.
17. Kirchhoff M, Rose H, Petersen BL, Maahr J, Gerdes T, et al. (1999)
Comparative genomic hybridization reveals a recurrent pattern of chromosomal
aberrations in severe dysplasia/carcinoma in situ of the cervix and in advanced-
stage cervical carcinoma. Genes Chromosomes Cancer 24: 144–150.
18. Bauer VL, Braselmann H, Henke M, Mattern D, Walch A, et al. (2008)
Chromosomal changes characterize head and neck cancer with poor prognosis.
J Mol Med 86: 1353–1365.
19. van den Broek GB, Wreesmann VB, van den Brekel MW, Rasch CR, Balm AJ,
et al. (2007) Genetic abnormalities associated with chemoradiation resistance of
head and neck squamous cell carcinoma. Clin Cancer Res 13: 4386–4391.
20. Heselmeyer K, Schrock E, du MS, Blegen H, Shah K, et al. (1996) Gain of
chromosome 3q defines the transition from severe dysplasia to invasive
carcinoma of the uterine cervix. Proc Natl Acad Sci U S A 93: 479–484.
21. Kersemaekers AM, van de Vijver MJ, Kenter GG, Fleuren GJ (1999) Genetic
alterations during the progression of squamous cell carcinomas of the uterine
cervix. Genes Chromosomes Cancer 26: 346–354.
22. Umayahara K, Numa F, Suehiro Y, Sakata A, Nawata S, et al. (2002)
Comparative genomic hybridization detects genetic alterations during early
stages of cervical cancer progression. Genes Chromosomes Cancer 33: 98–102.
23. Wilting SM, Steenbergen RD, Tijssen M, van Wieringen WN, Helmerhorst TJ,
et al. (2009) Chromosomal signatures of a subset of high-grade premalignant
cervical lesions closely resemble invasive carcinomas. Cancer Res 69: 647–655.
24. Maltepe E, Schmidt JV, Baunoch D, Bradfield CA, Simon MC (1997) Abnormal
angiogenesis and responses to glucose and oxygen deprivation in mice lacking
the protein ARNT. Nature 386: 403–407.
25. Chaineau M, Danglot L, Proux-Gillardeaux V, Galli T (2008) Role of HRB in
Clathrin-dependent Endocytosis. J Biol Chem 283: 34365–34373.
26. Tanaka N, Kyuuma M, Sugamura K (2008) Endosomal sorting complex
required for transport proteins in cancer pathogenesis, vesicular transport, and
non-endosomal functions. Cancer Sci 99: 1293–1303.
27. Lin CJ, Cencic R, Mills JR, Robert F, Pelletier J (2008) c-Myc and eIF4F are
components of a feedforward loop that links transcription and translation.
Cancer Res 68: 5326–5334.
28. Wouters BG, Koritzinsky M (2008) Hypoxia signalling through mTOR and the
unfolded protein response in cancer. Nat Rev Cancer 8: 851–864.
29. Wade PA (2001) Transcriptional control at regulatory checkpoints by histone
deacetylases: molecular connections between cancer and chromatin. Hum Mol
Genet 10: 693–698.
30. Imoto I, Tsuda H, Hirasawa A, Miura M, Sakamoto M, et al. (2002) Expression
of cIAP1, a target for 11q22 amplification, correlates with resistance of cervical
cancers to radiotherapy. Cancer Res 62: 4860–4866.
31. Narayan G, Bourdon V, Chaganti S, rias-Pulido H, Nandula SV, et al. (2007)
Gene dosage alterations revealed by cDNA microarray analysis in cervical
cancer: identification of candidate amplified and overexpressed genes. Genes
Chromosomes Cancer 46: 373–384.
32. Scotto L, Narayan G, Nandula SV, rias-Pulido H, Subramaniyam S, et al.
(2008) Identification of copy number gain and overexpressed genes on
chromosome arm 20q by an integrative genomic approach in cervical cancer:
potential role in progression. Genes Chromosomes Cancer 47: 755–765.
33. Scotto L, Narayan G, Nandula SV, Subramaniyam S, Kaufmann AM, et al.
(2008) Integrative genomics analysis of chromosome 5p gain in cervical cancer
reveals target over-expressed genes, including Drosha. Mol Cancer 7: 58.: 58.
34. Fyles A, Milosevic M, Hedley D, Pintilie M, Levin W, et al. (2002) Tumor
hypoxia has independent predictor impact only in patients with node-negative
cervix cancer. J Clin Oncol 20: 680–687.
35. Lyng H, Sundfor K, Trope C, Rofstad EK (2000) Disease control of uterine
cervical cancer: relationships to tumor oxygen tension, vascular density, cell
density, and frequency of mitosis and apoptosis measured before treatment and
during radiotherapy. Clin Cancer Res 6: 1104–1112.
36. Tsang RW, Wong CS, Fyles AW, Levin W, Manchul LA, et al. (1999) Tumour
proliferation and apoptosis in human uterine cervix carcinoma II: correlations
with clinical outcome. Radiother Oncol 50: 93–101.
37. Birch AH, Quinn MC, Filali-Mouhim A, Provencher DM, Mes-Masson AM,
et al. (2008) Transcriptome analysis of serous ovarian cancers identifies
differentially expressed chromosome 3 genes. Mol Carcinog 47: 56–65.
38. Novak RL, Phillips AC (2008) Adenoviral-mediated Rybp expression promotes
tumor cell-specific apoptosis. Cancer Gene Ther 15: 713–722.
39. Zheng L, Schickling O, Peter ME, Lenardo MJ (2001) The death effector
domain-associated factor plays distinct regulatory roles in the nucleus and
cytoplasm. J Biol Chem 276: 31945–31952.
40. Sanchez-Beato M, Sanchez E, Gonzalez-Carrero J, Morente M, Diez A, et al.
(2006) Variability in the expression of polycomb proteins in different normal and
tumoral tissues. A pilot study using tissue microarrays. Mod Pathol 19: 684–694.
41. Haussler MR, Haussler CA, Bartik L, Whitfield GK, Hsieh JC, et al. (2008)
Vitamin D receptor: molecular signaling and actions of nutritional ligands in
disease prevention. Nutr Rev 66: S98–112.
42. Rachez C, Lemon BD, Suldan Z, Bromleigh V, Gamble M, et al. (1999) Ligand-
dependent transcription activation by nuclear receptors requires the DRIP
complex. Nature 398: 824–828.
43. Zohn IE, Li Y, Skolnik EY, Anderson KV, Han J, et al. (2006) p38 and a p38-
interacting protein are critical for downregulation of E-cadherin during mouse
gastrulation. Cell 125: 957–969.
44. Han J, Sun P (2007) The pathways to tumor suppression via route p38. Trends
Biochem Sci 32: 364–371.
45. Bashyam MD, Bair R, Kim YH, Wang P, Hernandez-Boussard T, et al. (2005)
Array-based comparative genomic hybridization identifies localized DNA
amplifications and homozygous deletions in pancreatic cancer. Neoplasia 7:
556–562.
46. Kilic M, Kasperczyk H, Fulda S, Debatin KM (2007) Role of hypoxia inducible
factor-1 alpha in modulation of apoptosis resistance. Oncogene 26: 2027–2038.
47. Dong Z, Venkatachalam MA, Wang J, Patel Y, Saikumar P, et al. (2001) Up-
regulation of apoptosis inhibitory protein IAP-2 by hypoxia. Hif-1-independent
mechanisms. J Biol Chem 276: 18702–18709.
48. Low WK, Dang Y, Schneider-Poetsch T, Shi Z, Choi NS, et al. (2005) Inhibition
of eukaryotic translation initiation by the marine natural product pateamine A.
Mol Cell 20: 709–722.
49. Ron D, Hinnebusch AG (2006) Targeting translation in hypoxic tumors. ACS
Chem Biol 1: 145–148.
50. Lyng H, Brovig RS, Svendsrud DH, Holm R, Kaalhus O, et al. (2006) Gene
expressions and copy numbers associated with metastatic phenotypes of uterine
cervical cancer. BMC Genomics 7: 268.
51. Hupe P, Stransky N, Thiery JP, Radvanyi F, Barillot E (2004) Analysis of array
CGH data: from signal ratio to gain and loss of DNA regions. Bioinformatics 20:
3413–3422.
52. Benjamini Y, Hochberg Y (2008) Controlling the false discoveryrate: a practical
and powerful approach to multiple testing. Journal of R Stat Soc B 57: 289–300.
53. Tibshirani R (1997) The lasso method for variable selection in the Cox model.
Stat Med 16: 385–395.
54. Bovelstad HM, Nygard S, Storvold HL, Aldrin M, Borgan O, et al. (2007)
Predicting survival from microarray data - a comparative study. Bioinformatics
23: 2080–2087.
55. Zou H, Hastie T (2005) Regularization and variable selection via the elastic net.
J R Statist Soc B 67: 301–320.
Driver Genes in Cervical Cancer
PLoS Genetics | www.plosgenetics.org 12 November 2009 | Volume 5 | Issue 11 | e1000719
Supplementary Figure 1
55
50
Total (n=97)A B
HPV negative
tumors (n=8)
Adenosquamous
carcinomas (n=5)Ploidy
45
40
35
30
25
20
15
10N
um
b
er
 o
f 
p
at
ie
nt
s
213 8 4 2
003.4-3.6
112.8-3.2
002.4-2.6
531.8-2.2 a
Adenosquamous carcinomas (n=5)
5
0
1.8-2.2    2.4-2.6    2.8-3.2    3.4-3.6    3.8-4.2     >4.2
N
Ploidy
C
00>4.2
. - .
aNumber of patients is indicated
100
80
60
40
20
0
20
40q
ue
nc
y 
(%
)
60
80
100
1               2             3              4          5            6          7          8         9       10      11    12       13    14   15  16  17  18 19 20 21 22 X
F
re
q
Chromosome
HPV negative tumors (n=8)
D
100
80
60
40
20
0
20
40eq
ue
nc
y 
(%
)
60
80
100
1               2             3              4          5            6          7          8         9       10      11    12       13    14   15  16  17  18 19 20 21 22 X
F
re
Chromosome
Supplementary Figure 1
Tumor ploidy and gene dosage alterations in relation to histological type and HPV status. (A) 
Ploidy distribution of 97 patients. Tumors with a ploidy within the range of 1.8–2.2 were 
considered as near diploid. (B) Ploidy of patients with adenosquamous carcinoma or HPV 
negative tumor. (C, D) Frequency of patients with gains (red) and losses (green) along 
chromosome 1 to X for patients with adenosquamous carcinoma (C) and HPV negative 
tumor (D). Gene dosage alterations above 1.1 and below 0.9 were classified as gains and 
losses, respectively. (A–D) Tumors in the basic cohort subjected to aCGH analysis were 
included.
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Supplementary Figure 2
Tumor ploidy and gene dosage alterations in homogeneous and heterogeneous tumors. (A)
Ploidy distribution of patients with homogeneous (left) and heterogeneous (right) tumors. 
(B,C) Frequency of patients with gains (red) and losses (green) along chromosome 1 to X for 
patients with homogeneous (B) and heterogeneous (C) tumor. Gene dosage alterations 
above 1.1 and below 0.9 were classified as gains and losses, respectively. Totally 86 patients 
with a tumor cell fraction sufficiently high for reliable detection of heterogeneity were included 
in the analysis.
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Supplementary Figure 3
Clinical outcome for patients with different combinations of predictive losses. Kaplan-Meier curves showing 
progression free survival after chemoradiotherapy of 97 cervical cancer patients with different combinations of 
3p11.2-p14.1, 13q13.1-q21.1, and 21q22.2-3 loss. The different combinations and number of patients in each 
group are listed (right). P-value in log-rank test is indicated.
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C l ti b t d d i T i l l ti l t forre a ons e ween gene osage an  express on. yp ca  corre a on p o s o  gene 
dosage and expression for 9 correlating genes within the recurrent and predictive 
regions; 6 with gain and 3 with loss. Spearman's rank correlation analysis on semi-
discrete data was performed, for which amplitudes lower than 1.1 were set to 1 for gains 
and amplitudes higher than 0.9 were set to 1 for losses. Correlation coefficient (R) and 
p-value are indicated.
Table S1. Recurrent high level amplifications and homozygous deletions in locally advanced cervical cancer.
Peak regiona Peak regiona Freq.b Max./min. gene dosagec Correlating genes
d
(Cytoband) (MB) (%) (copy no.) 
Recurrent high level amplification 
3q26.1-qter 166.2-199.5 8 4.5 (9) 
PDCD10, PHC3, ZNF639, FXR1, PARL, DVL3, ABCF3, ALG3, 
EIF4G1, SFRS10, DGKG, EIF4A2,  RFC4, CCDC50, PPP1R2, 
PAK2, NCBP2, DLG1, BDH1, FLYTTD1 
5p15.2-pter 1.0-12.1 8 4 (15) CLPTM1L , MED10, FASTKD3, CCT5, DAP 
9p24.1-2 2.7-6.0 4 13.5 (27) KIAA0020, RCL1 
11q13.2-3 68.6-70.6 4 10 (20) FADD
11q22.1-2 100.2-102.0 5 36 (72) YAP1, BIRC3, BIRC2 
20q11.21-22 30.0-33.0 5 3.4 (9) POFUT1, KIF3B, MAPRE1, SNTA1, EIF2S2, AHCY 
21q22.11-2 32.9-39.6 4 7.5 (15) TTC3, BRWD1 
Homozygous deletione
5q13.2 67.4-71.7 1 0 (0) SMN2 
6p21.1-p12.1 44.1-54.1 1 0 (0) -
8q24.23 136.6-139.3 1 0 (0) -
9p21.1-3 22.6-29.6 1 0 (0) MOBKL2B
10q23.31 88.2-92.1 3 0 (0) -
13q34 111.7-114.1 1 0 (0) -
aPeak region of high level amplifications is the region with more than 25% higher amplitude than surrounding region. Peak region of 
homozygote deletions is the region with a gene dosage of zero.  
bFrequency is the median percentage of tumors with the alteration. 
cGene dosage is absolute DNA copy number divided by ploidy. Maximum (gain) or minimum (loss) gene dosage and the 
corresponding copy number are listed. 
dGenes within the peak region showing a correlation between gene dosage and expression are ordered by DNA location. 
eHomozygote deletions were seen in only few tumors and were not detected as recurrent in statistical analysis. 
Table S2. Relationships between Illumina, cDNA, and gene dosage data for correlating genesa.
Reporter
ID IlluminaID Gene
cDNA vs gene 
dosage
cDNA vs gene 
dosage cDNA vs Illumina 
Illumina vs gene 
dosage
95 patients 52 patients 
R p R p R p R p
129563 ILMN_1762582 ARNT 0.407 0.000 0.403 0.004 0.412 0.003 0.411 0.003
814158 ILMN_1669113 ATF5 0.347 0.001 0.520 0.000 0.812 0.000 0.488 0.000
825312 ILMN_1772929 ATP5J 0.369 0.002 0.421 0.007 0.611 0.000 0.368 0.010
877832 ILMN_1853837 BCAP31 0.327 0.001 0.225 0.111 0.866 0.000 0.280 0.047
782748 ILMN_1708485 BIN3 0.502 0.000 0.577 0.000 0.345 0.013 0.415 0.003
34852 ILMN_1768194 BIRC2 0.475 0.000 0.467 0.000 0.697 0.000 0.573 0.000
201890 ILMN_2405684 BIRC3 0.476 0.000 0.445 0.001 0.636 0.000 0.237 0.091
249618 ILMN_1752802 CLPTM1L 0.367 0.001 0.484 0.002 0.517 0.000 0.701 0.000
343352 ILMN_1779530 COG6 0.403 0.000 0.510 0.000 0.622 0.000 0.451 0.002
897971 ILMN_1699112 COPB1 0.345 0.001 0.579 0.000 0.468 0.000 0.556 0.000
884480 ILMN_1798189 COX7C 0.500 0.000 0.341 0.017 0.609 0.000 0.407 0.004
814381 ILMN_2112493 DAP 0.404 0.000 0.565 0.000 0.790 0.000 0.621 0.000
487082 ILMN_1706498 DSE 0.378 0.000 0.365 0.010 0.586 0.000 0.444 0.002
22918 ILMN_1768127 EBNA1BP2 0.293 0.004 0.242 0.086 0.696 0.000 0.352 0.012
469151 ILMN_1798014 EIF2S2 0.508 0.000 0.571 0.000 0.444 0.001 0.439 0.001
810237 ILMN_1665717 EIF2S3 0.427 0.000 0.248 0.076 0.492 0.000 0.320 0.021
307532 ILMN_1685722 EIF4A2 0.434 0.000 0.459 0.000 0.633 0.000 0.552 0.000
25988 ILMN_2370772 EIF4G1 0.468 0.000 0.314 0.038 0.636 0.000 0.446 0.002
809453 ILMN_1802376 FAM48A 0.415 0.000 0.349 0.016 0.492 0.000 0.344 0.018
133158 ILMN_1750160 FASTKD3 0.619 0.000 0.782 0.000 0.645 0.000 0.608 0.000
82171 ILMN_1687940 FOXO3 0.335 0.002 0.315 0.033 0.618 0.000 0.359 0.015
289551 ILMN_2389273 FXR1 0.435 0.000 0.530 0.000 0.752 0.000 0.554 0.000
127509 ILMN_1789702 GBE1 0.347 0.001 0.271 0.057 0.465 0.000 0.365 0.009
754085 ILMN_1745798 GTF2F2 0.344 0.001 0.473 0.000 0.700 0.000 0.480 0.000
811942 ILMN_2157957 GTF2H1 0.341 0.001 0.323 0.021 0.449 0.000 0.215 0.130
256664 ILMN_2200331 H2AFX 0.388 0.000 0.305 0.036 0.495 0.000 0.332 0.021
502669 ILMN_1767747 HDAC2 0.439 0.000 0.471 0.000 0.521 0.000 0.652 0.000
1606829 ILMN_1764396 HDAC4 0.357 0.001 0.397 0.005 0.395 0.004 0.301 0.036
843319 ILMN_1792497 HRB 0.425 0.000 0.466 0.000 0.292 0.036 0.415 0.002
810942 ILMN_1802706 IDH3G 0.428 0.000 0.486 0.000 0.789 0.000 0.275 0.051
795282 ILMN_1664641 MED4 0.568 0.000 0.502 0.000 0.445 0.001 0.446 0.003
131653 ILMN_2371964 MRPS12 0.455 0.000 0.521 0.000 0.785 0.000 0.548 0.000
810979 ILMN_1815043 MRPS2 0.365 0.001 0.333 0.018 0.495 0.000 0.507 0.000
470216 ILMN_1727080 MYO6 0.373 0.000 0.219 0.122 0.298 0.032 0.373 0.007
26711 ILMN_1720442 NCBP2 0.494 0.000 0.442 0.002 0.590 0.000 0.682 0.000
753457 ILMN_1728810 NDUFS1 0.431 0.000 0.405 0.004 0.383 0.005 0.476 0.000
795439 ILMN_2323491 NUP62 0.318 0.002 0.438 0.002 0.281 0.044 0.451 0.001
134439 ILMN_1712687 PAK2 0.304 0.003 0.245 0.093 0.414 0.002 0.568 0.000
137836 ILMN_2269002 PDCD10 0.588 0.000 0.646 0.000 0.775 0.000 0.705 0.000
80374 ILMN_1772369 PDHA1 0.327 0.001 0.177 0.214 0.743 0.000 0.207 0.144
248454 ILMN_1815261 PDIA4 0.357 0.001 0.289 0.049 0.621 0.000 0.445 0.002
454475 ILMN_1814074 PHKA2 0.470 0.000 0.298 0.036 0.656 0.000 0.418 0.003
112131 ILMN_1776076 POFUT1 0.303 0.003 0.476 0.000 0.662 0.000 0.457 0.000
2191807 ILMN_1773613 POU2F3 0.399 0.000 0.257 0.113 0.295 0.052 0.120 0.431
769657 ILMN_1683044 PPP1R2 0.524 0.000 0.551 0.000 0.558 0.000 0.637 0.000
125148 ILMN_1813766 RCL1 0.603 0.000 0.492 0.000 0.719 0.000 0.515 0.000
853151 ILMN_1651850 RPS16 0.440 0.000 0.418 0.002 0.042 0.766 0.169 0.236
795453 ILMN_1721842 RYBP 0.494 0.000 0.606 0.000 0.522 0.000 0.480 0.000
450131 ILMN_1752111 SMARCAL1 0.437 0.000 0.614 0.000 0.521 0.000 0.625 0.000
295255 ILMN_1788211 SNX19 0.422 0.000 0.417 0.006 0.671 0.000 0.440 0.003
884657 ILMN_1738938 TIMM8B 0.432 0.000 0.649 0.000 0.717 0.000 0.587 0.000
878744 ILMN_1747146 TSG101 0.538 0.000 0.554 0.000 0.632 0.000 0.549 0.000
739126 ILMN_1697777 TSTA3 0.387 0.000 0.336 0.020 0.336 0.000 0.222 0.128
346292 ILMN_1675674 UBE4B 0.304 0.003 0.460 0.001 0.661 0.000 0.367 0.011
206545 ILMN_2174884 XPO7 0.400 0.000 0.434 0.001 0.742 0.000 0.614 0.000
126702 ILMN_1792990 ZNF202 0.333 0.001 0.355 0.013 0.289 0.038 0.387 0.006
aData for the genes in Figure 5 are shown, except for SLC25A6 which was not included in the Illumina data set.
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